SI0823900T1 - - Google Patents

Info

Publication number: SI0823900T1
Authority: SI; Slovenia

Application number

SI9630183T

Inventor

Keith Hopkinson Gibson

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-27

Filing date

1996-04-23

Publication date

2001-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10773597&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0823900(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-04-23 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2001-06-30 Publication of SI0823900T1 publication Critical patent/SI0823900T1/xx

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms

SI9630183T 1995-04-27 1996-04-23 SI0823900T1 (xx)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9508538.7A GB9508538D0 (en)	1995-04-27	1995-04-27	Quinazoline derivatives
EP96910134A EP0823900B1 (en)	1995-04-27	1996-04-23	Quinazoline derivatives
PCT/GB1996/000961 WO1996033980A1 (en)	1995-04-27	1996-04-23	Quinazoline derivatives

Publications (1)

Publication Number	Publication Date
SI0823900T1 true SI0823900T1 (xx)	2001-06-30

Family

ID=10773597

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI9630183T SI0823900T1 (xx)	1995-04-27	1996-04-23

Country Status (39)

Country	Link
US (1)	US5770599A (xx)
EP (1)	EP0823900B1 (xx)
JP (1)	JP3040486B2 (xx)
KR (1)	KR100296656B1 (xx)
CN (1)	CN1100046C (xx)
AR (1)	AR003944A1 (xx)
AT (1)	ATE198329T1 (xx)
AU (1)	AU699163B2 (xx)
BG (1)	BG62730B1 (xx)
BR (1)	BRPI9608082B8 (xx)
CA (1)	CA2215732C (xx)
CZ (1)	CZ288489B6 (xx)
DE (2)	DE122009000076I1 (xx)
DK (1)	DK0823900T3 (xx)
EE (1)	EE03482B1 (xx)
EG (1)	EG24134A (xx)
ES (1)	ES2153098T3 (xx)
FR (1)	FR09C0065I2 (xx)
GB (1)	GB9508538D0 (xx)
GR (1)	GR3035211T3 (xx)
HK (1)	HK1005371A1 (xx)
HR (1)	HRP960204B1 (xx)
HU (1)	HU223313B1 (xx)
IL (1)	IL118045A (xx)
LU (1)	LU91631I2 (xx)
MY (1)	MY114425A (xx)
NL (1)	NL300429I1 (xx)
NO (2)	NO309472B1 (xx)
NZ (1)	NZ305444A (xx)
PL (1)	PL189182B1 (xx)
PT (1)	PT823900E (xx)
RO (1)	RO117849B1 (xx)
RU (1)	RU2153495C2 (xx)
SI (1)	SI0823900T1 (xx)
SK (1)	SK282236B6 (xx)
TW (1)	TW436486B (xx)
UA (1)	UA52602C2 (xx)
WO (1)	WO1996033980A1 (xx)
ZA (1)	ZA963358B (xx)

Families Citing this family (698)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6811779B2 (en)	1994-02-10	2004-11-02	Imclone Systems Incorporated	Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
TW321649B (xx) *	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
GB9508537D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508535D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
GB9508565D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
EP0824525B1 (en) *	1995-04-27	2001-06-13	AstraZeneca AB	Quinazoline derivatives
US7060808B1 (en) *	1995-06-07	2006-06-13	Imclone Systems Incorporated	Humanized anti-EGF receptor monoclonal antibody
GB9624482D0 (en) *	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
US6184225B1 (en)	1996-02-13	2001-02-06	Zeneca Limited	Quinazoline derivatives as VEGF inhibitors
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
GB9603097D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline compounds
DE69709319T2 (de)	1996-03-05	2002-08-14	Astrazeneca Ab	4-anilinochinazolin derivate
BR9708640B1 (pt)	1996-04-12	2013-06-11		inibidores irreversÍveis de tirosina-cinases e composiÇço farmacÊutica compreendendo os mesmo.
GB9607729D0 (en) *	1996-04-13	1996-06-19	Zeneca Ltd	Quinazoline derivatives
GB9718972D0 (en) *	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
EA002525B1 (ru) *	1997-08-15	2002-06-27	Сефалон Инк.	Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
AU8816298A (en)	1997-08-22	1999-03-16	Zeneca Limited	Oxindolylquinazoline derivatives as angiogenesis inhibitors
US20030224001A1 (en) *	1998-03-19	2003-12-04	Goldstein Neil I.	Antibody and antibody fragments for inhibiting the growth of tumors
US6864227B1 (en)	1998-04-13	2005-03-08	California Institute Of Technology	Artery-and vein-specific proteins and uses therefor
US6887674B1 (en)	1998-04-13	2005-05-03	California Institute Of Technology	Artery- and vein-specific proteins and uses therefor
ZA200007412B (en) *	1998-05-15	2002-03-12	Imclone Systems Inc	Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
CZ2001584A3 (cs)	1998-08-18	2002-06-12	The Regents Of The University Of California	Prevence tvorby hlenu v dýchacích cestách podáváním antagonistů EGF-R
US7354894B2 (en) *	1998-08-18	2008-04-08	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
JP2002523403A (ja) *	1998-08-21	2002-07-30	パーカーヒューズインスティテュート	キナゾリン誘導体
US6288082B1 (en)	1998-09-29	2001-09-11	American Cyanamid Company	Substituted 3-cyanoquinolines
US6297258B1 (en)	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
BRPI9914164B8 (pt)	1998-09-29	2021-05-25	American Cyanamid Co	compostos de 3-ciano quinolina
IL142921A0 (en) *	1998-11-20	2002-04-21	Genentech Inc	USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
SK12112001A3 (sk)	1999-02-27	2001-12-03	Boehringer Ingelheim Pharma Kg	4-amino-chinazolínové a chinolínové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
DE19911509A1 (de) *	1999-03-15	2000-09-21	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
BR0010524A (pt) *	1999-05-14	2002-05-28	Imclone Systems Inc	Tratamento de tumores humanos refratários com antagonistas de receptor de fator de crescimento epidérmico
MXPA01012899A (es)	1999-06-21	2002-07-30	Boehringer Ingelheim Pharma	Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
US6432979B1 (en)	1999-08-12	2002-08-13	American Cyanamid Company	Method of treating or inhibiting colonic polyps and colorectal cancer
GB9925958D0 (en) *	1999-11-02	1999-12-29	Bundred Nigel J	Therapeutic use
KR100849151B1 (ko) *	1999-11-05	2008-07-30	아스트라제네카 아베	Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
US20020002169A1 (en)	1999-12-08	2002-01-03	Griffin John H.	Protein kinase inhibitors
GB0002952D0 (en) *	2000-02-09	2000-03-29	Pharma Mar Sa	Process for producing kahalalide F compounds
GB0007371D0 (en)	2000-03-28	2000-05-17	Astrazeneca Uk Ltd	Chemical compounds
GB0008368D0 (en) *	2000-04-06	2000-05-24	Astrazeneca Ab	Combination product
MXPA02009891A (es)	2000-04-07	2003-03-27	Astrazeneca Ab	Compuestos de quinazolina.
EP1170011A1 (en) *	2000-07-06	2002-01-09	Boehringer Ingelheim International GmbH	Novel use of inhibitors of the epidermal growth factor receptor
EP1311291A4 (en) *	2000-08-09	2007-07-25	Imclone Systems Inc	TREATMENT OF HYPERPROLIFERATIVE DISEASES USING EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS
US6740651B2 (en)	2000-08-26	2004-05-25	Boehringer Ingelheim Pharma Kg	Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042059A1 (de) *	2000-08-26	2002-03-07	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6617329B2 (en)	2000-08-26	2003-09-09	Boehringer Ingelheim Pharma Kg	Aminoquinazolines and their use as medicaments
US6656946B2 (en)	2000-08-26	2003-12-02	Boehringer Ingelheim Pharma Kg	Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
DE10042058A1 (de) *	2000-08-26	2002-03-07	Boehringer Ingelheim Pharma	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6403580B1 (en)	2000-08-26	2002-06-11	Boehringer Ingelheim Pharma Kg	Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US6939866B2 (en) *	2000-10-13	2005-09-06	Astrazeneca Ab	Quinazoline derivatives
TWI304061B (en)	2000-10-20	2008-12-11	Eisai R&D Man Co Ltd	Nitrogen-containing aromatic ring derivatives
US7776315B2 (en)	2000-10-31	2010-08-17	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions based on anticholinergics and additional active ingredients
DE10206505A1 (de) *	2002-02-16	2003-08-28	Boehringer Ingelheim Pharma	Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern
WO2002036587A2 (en) *	2000-11-01	2002-05-10	Cor Therapeutics, Inc.	Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
US7019012B2 (en)	2000-12-20	2006-03-28	Boehringer Ingelheim International Pharma Gmbh & Co. Kg	Quinazoline derivatives and pharmaceutical compositions containing them
CA2994779C (en)	2001-02-19	2020-08-25	Novartis Ag	Use of 40-o-(2-hydroxyethyl)-rapamycin for inhibiting growth of a solid tumour of the brain other than lymphatic cancer
US20080008704A1 (en) *	2001-03-16	2008-01-10	Mark Rubin	Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
BR0209647A (pt)	2001-05-16	2004-07-27	Novartis Ag	Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico
EP1408980A4 (en)	2001-06-21	2004-10-20	Ariad Pharma Inc	NEW QUINAZOLINES AND THEIR USE
DE10204462A1 (de) *	2002-02-05	2003-08-07	Boehringer Ingelheim Pharma	Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
JP4389205B2 (ja)	2002-02-06	2009-12-24	宇部興産株式会社	４−アミノキナゾリン化合物の製法
WO2003072139A1 (en) *	2002-02-26	2003-09-04	Astrazeneca Ab	Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
ATE465738T1 (de) *	2002-02-26	2010-05-15	Astrazeneca Ab	Neue kristalline formen der krebsbekämpfenden verbindung zd1839
GB0204392D0 (en) *	2002-02-26	2002-04-10	Astrazeneca Ab	Pharmaceutical compound
US20040132101A1 (en)	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
TWI324597B (en) *	2002-03-28	2010-05-11	Astrazeneca Ab	Quinazoline derivatives
US6924285B2 (en)	2002-03-30	2005-08-02	Boehringer Ingelheim Pharma Gmbh & Co.	Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1496909B1 (en) *	2002-04-16	2007-02-14	AstraZeneca AB	Combination therapy for the treatment of cancer
DE10221018A1 (de) *	2002-05-11	2003-11-27	Boehringer Ingelheim Pharma	Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
PL372103A1 (en)	2002-05-16	2005-07-11	Novartis Ag	Use of edg receptor binding agents in cancer
US20040048887A1 (en) *	2002-07-09	2004-03-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors
EP2277867B1 (en)	2002-07-15	2012-12-05	Symphony Evolution, Inc.	Compounds, pharmaceutical compositions thereof and their use in treating cancer
JP5069843B2 (ja)	2002-07-15	2012-11-07	ジェネンテック，インコーポレイテッド	抗ＥｒｂＢ２抗体を用いる処置に応答性である腫瘍を同定するための方法
GB0221245D0 (en) *	2002-09-13	2002-10-23	Astrazeneca Ab	Chemical process
CN1705491B (zh)	2002-09-27	2013-05-29	赞科股份有限公司	优化的Fc变体及其产生方法
GB0223854D0 (en) *	2002-10-12	2002-11-20	Astrazeneca Ab	Therapeutic treatment
GB0304367D0 (en) *	2003-02-26	2003-04-02	Pharma Mar Sau	Methods for treating psoriasis
EP1567506A4 (en)	2002-11-20	2007-06-20	Array Biopharma Inc	CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
JPWO2004060400A1 (ja) *	2003-01-06	2006-05-11	那波　宏之	上皮成長因子受容体を分子標的とする抗精神病薬
SG182004A1 (en)	2003-01-14	2012-07-30	Arena Pharm Inc	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
GB0302882D0 (en) *	2003-02-07	2003-03-12	Univ Cardiff	Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss
US7223749B2 (en)	2003-02-20	2007-05-29	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US7994159B2 (en)	2003-03-10	2011-08-09	Eisai R&D Management Co., Ltd.	c-Kit kinase inhibitor
US7381410B2 (en) *	2003-03-12	2008-06-03	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1605961A4 (en) *	2003-03-12	2009-11-11	Vasgene Therapeutics Inc	POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
EP1622941A2 (en) *	2003-03-20	2006-02-08	ImClone Systems Incorporated	Method of producing an antibody to epidermal growth factor receptor
GB0309850D0 (en)	2003-04-30	2003-06-04	Astrazeneca Ab	Quinazoline derivatives
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent
CL2004001120A1 (es)	2003-05-19	2005-04-15	Irm Llc	Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
MY150088A (en)	2003-05-19	2013-11-29	Irm Llc	Immunosuppressant compounds and compositions
PA8603801A1 (es)	2003-05-27	2004-12-16	Janssen Pharmaceutica Nv	Derivados de la quinazolina
KR101126560B1 (ko)	2003-05-30	2012-04-05	도꾜 다이가꾸	약제 반응 예측 방법
DE10326186A1 (de) *	2003-06-06	2004-12-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP2389953A1 (en)	2003-06-09	2011-11-30	Samuel Waksal	Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular antagonist
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
KR20110129988A (ko)	2003-07-18	2011-12-02	암젠 인코포레이티드	간세포 성장인자에 결합하는 특이 결합제
GB0317665D0 (en)	2003-07-29	2003-09-03	Astrazeneca Ab	Qinazoline derivatives
GB0317663D0 (en) *	2003-07-29	2003-09-03	Astrazeneca Ab	Pharmaceutical composition
CA2533345A1 (en) *	2003-07-29	2005-02-10	Astrazeneca Ab	Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
GB0320793D0 (en) *	2003-09-05	2003-10-08	Astrazeneca Ab	Chemical process
GB0321066D0 (en) *	2003-09-09	2003-10-08	Pharma Mar Sau	New antitumoral compounds
US20080234263A1 (en) *	2003-09-16	2008-09-25	Laurent Francois Andre Hennequin	Quinazoline Derivatives
ATE395346T1 (de) *	2003-09-16	2008-05-15	Astrazeneca Ab	Chinazolinderivate als tyrosinkinaseinhibitoren
AU2004274227B2 (en) *	2003-09-19	2008-04-24	Astrazeneca Ab	Quinazoline derivatives
JP2007505878A (ja) *	2003-09-19	2007-03-15	アストラゼネカアクチボラグ	キナゾリン誘導体
GB0322409D0 (en)	2003-09-25	2003-10-29	Astrazeneca Ab	Quinazoline derivatives
US20070043010A1 (en) *	2003-09-25	2007-02-22	Astrazeneca Uk Limited	Quinazoline derivatives
EP2609919A3 (en) *	2003-09-26	2014-02-26	Exelixis, Inc.	c-Met modulators and methods of use
US7456189B2 (en)	2003-09-30	2008-11-25	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (de)	2003-10-17	2005-05-12	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Aminocrotonylverbindungen
BR122018071808B8 (pt)	2003-11-06	2020-06-30	Seattle Genetics Inc	conjugado
JP4303726B2 (ja)	2003-11-11	2009-07-29	エーザイ・アール・アンド・ディー・マネジメント株式会社	ウレア誘導体およびその製造方法
GB0326459D0 (en)	2003-11-13	2003-12-17	Astrazeneca Ab	Quinazoline derivatives
US7799772B2 (en)	2003-12-18	2010-09-21	Janssen Pharmaceutica N.V.	Pyrido-and pyrimidopyrimidine derivatives as anti-profilerative agents
WO2005062041A1 (en) *	2003-12-24	2005-07-07	Astrazeneca Ab	Pharmaceutical dissolution testing using a non-ionic surfactant
WO2005070909A1 (en) *	2004-01-22	2005-08-04	Natco Pharma Limited	An improved process for the preparation of gefitinib
JP5032851B2 (ja)	2004-02-03	2012-09-26	アストラゼネカアクチボラグ	キナゾリン誘導体
ATE492564T1 (de)	2004-03-12	2011-01-15	Vasgene Therapeutics Inc	Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
CN101072797B (zh) *	2004-03-12	2012-05-09	瓦斯基因治疗公司	结合ephb4、抑制血管发生和肿瘤生长的抗体
US7598350B2 (en)	2004-03-19	2009-10-06	Imclone Llc	Human anti-epidermal growth factor receptor antibody
EP2423331B1 (en)	2004-03-31	2019-05-08	The General Hospital Corporation	Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
WO2005097134A2 (en) *	2004-03-31	2005-10-20	The Scripps Research Institute	Quinazoline based protein kinase inhibitors
AU2005231956B2 (en)	2004-04-07	2009-11-05	Novartis Ag	Inhibitors of IAP
KR20080095915A (ko) *	2004-05-06	2008-10-29	워너-램버트 캄파니 엘엘씨	4-페닐아미노-퀴나졸린-6-일-아미드
US8080577B2 (en)	2004-05-06	2011-12-20	Bioresponse, L.L.C.	Diindolylmethane formulations for the treatment of leiomyomas
BRPI0510883B8 (pt)	2004-06-01	2021-05-25	Genentech Inc	composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
GB0512324D0 (en)	2005-06-16	2005-07-27	Novartis Ag	Organic compounds
EP1765313A2 (en)	2004-06-24	2007-03-28	Novartis Vaccines and Diagnostics, Inc.	Compounds for immunopotentiation
AU2005272993B2 (en)	2004-07-15	2010-02-11	Xencor, Inc	Optimized Fc variants
US8969379B2 (en)	2004-09-17	2015-03-03	Eisai R&D Management Co., Ltd.	Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
AU2005286662B2 (en)	2004-09-23	2011-10-06	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
RU2412947C2 (ru)	2004-09-23	2011-02-27	Дженентек, Инк.	Антитела, сконструированные на основе цистеинов, и их конъюгаты
JO3000B1 (ar)	2004-10-20	2016-09-05	Genentech Inc	مركبات أجسام مضادة .
ES2450566T3 (es)	2004-11-30	2014-03-25	Amgen Inc.	Análogos de quinazolina y quinolinas y su uso como medicamentos para tratar el cáncer
NI200700147A (es) *	2004-12-08	2019-05-10	Janssen Pharmaceutica Nv	Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) *	2004-12-08	2017-03-15	Janssen Pharmaceutica Nv	مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
CN101124228B (zh)	2004-12-14	2011-06-15	阿斯利康(瑞典)有限公司	用作抗肿瘤药物的吡唑并嘧啶化合物
EP1838303B1 (en)	2004-12-30	2011-02-09	Bioresponse LLC	Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associates conditions
DOP2006000010A (es)	2005-01-10	2006-07-31	Arena Pharm Inc	Procedimiento para preparar eteres aromáticos
BRPI0606480A (pt)	2005-01-21	2008-03-11	Astex Therapeutics Ltd	compostos farmacêuticos
KR20190110637A (ko)	2005-01-21	2019-09-30	제넨테크, 인크.	Ｈｅｒ 항체의 고정 용량 투여법
GB0501999D0 (en) *	2005-02-01	2005-03-09	Sentinel Oncology Ltd	Pharmaceutical compounds
DK1848414T3 (da)	2005-02-03	2011-07-25	Gen Hospital Corp	Fremgangsmåde til behandling af gefitinib-resistent cancer
US20090155247A1 (en) *	2005-02-18	2009-06-18	Ashkenazi Avi J	Methods of Using Death Receptor Agonists and EGFR Inhibitors
US20060188498A1 (en) *	2005-02-18	2006-08-24	Genentech, Inc.	Methods of using death receptor agonists and EGFR inhibitors
WO2006090413A1 (en) *	2005-02-23	2006-08-31	Natco Pharma Limited	Novel crystalline form of gefitinib and a process for its preparation
RU2404806C2 (ru)	2005-02-23	2010-11-27	Дженентек, Инк.	Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
CA2599210A1 (en)	2005-02-26	2006-08-31	Astrazeneca Ab	Quinazoline derivatives as tyrosine kinase inhibitors
DE602006021401D1 (de)	2005-02-28	2011-06-01	Eisai R&D Man Co Ltd	Neue kombinierte anwendung einer sulfonamid-verbindung zur behandlung von krebs
US20060216288A1 (en) *	2005-03-22	2006-09-28	Amgen Inc	Combinations for the treatment of cancer
US8309133B2 (en) *	2005-04-12	2012-11-13	Alkermes Pharma Ireland Limited	Nanoparticulate quinazoline derivative formulations
LT1871347T (lt)	2005-04-19	2016-11-10	Novartis Ag	Farmacinė kompozicija
WO2006119674A1 (fr) *	2005-05-12	2006-11-16	Wenlin Huang	Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale
WO2006119673A1 (fr) *	2005-05-12	2006-11-16	Wenlin Huang	Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale
WO2006119676A1 (fr) *	2005-05-12	2006-11-16	Wenlin Huang	Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d'une maladie tumorale
BRPI0610360A2 (pt)	2005-05-13	2010-06-15	Novartis Ag	métodos para tratar de cáncer resistente a fármaco
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
CN101613409B (zh)	2005-06-17	2014-06-04	英克隆有限责任公司	抗-PDGFRα抗体
NZ565654A (en) *	2005-07-18	2010-10-29	Bipar Sciences Inc	Use of iodonitrobenzamide compounds for the treatment of ovarian cancer
JP5066446B2 (ja) *	2005-08-01	2012-11-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	血管新生阻害物質の効果を予測する方法
EP1925676A4 (en)	2005-08-02	2010-11-10	Eisai R&D Man Co Ltd	TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
US8129114B2 (en)	2005-08-24	2012-03-06	Bristol-Myers Squibb Company	Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
CN1300118C (zh) *	2005-08-25	2007-02-14	江苏吴中苏药医药开发有限责任公司	4－(3－氯－4－氟苯基胺基)－7－甲氧基－6－(3－吗啉丙氧基)喹唑啉的制备方法
WO2007026864A1 (ja) *	2005-09-01	2007-03-08	Eisai R & D Management Co., Ltd.	崩壊性の改善された医薬組成物の製造方法
DE602006018331D1 (de)	2005-09-20	2010-12-30	Astrazeneca Ab	4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
WO2007038395A2 (en) *	2005-09-23	2007-04-05	Vasgene Therapeutics, Inc.	Use of ephrinb2 directed agents for the treatment or prevention of viral infections
RU2451524C2 (ru)	2005-11-04	2012-05-27	Вайет	Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
AU2006309551B2 (en) *	2005-11-07	2012-04-19	Eisai R & D Management Co., Ltd.	Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
WO2007054550A1 (en)	2005-11-11	2007-05-18	Boehringer Ingelheim International Gmbh	Quinazoline derivatives for the treatment of cancer diseases
PT2275103E (pt)	2005-11-21	2014-07-24	Novartis Ag	Inibidores de mtor para o tratamento de tumores endócrinos
US20090247576A1 (en) *	2005-11-22	2009-10-01	Eisai R & D Management Co., Ltd.	Anti-tumor agent for multiple myeloma
US7977346B2 (en) *	2006-01-17	2011-07-12	Guoqing Paul Chen	Spiro compounds and methods of use
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
CN101003514A (zh) *	2006-01-20	2007-07-25	上海艾力斯医药科技有限公司	喹唑啉衍生物、其制备方法及用途
AR059066A1 (es)	2006-01-27	2008-03-12	Amgen Inc	Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
PE20070978A1 (es) *	2006-02-14	2007-11-15	Novartis Ag	COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
GB0605120D0 (en)	2006-03-14	2006-04-26	Novartis Ag	Organic Compounds
US20070231298A1 (en) *	2006-03-31	2007-10-04	Cell Genesys, Inc.	Cytokine-expressing cancer immunotherapy combinations
US20090098137A1 (en)	2006-04-05	2009-04-16	Novartis Ag	Combinations of therapeutic agents for treating cancer
EP2606890A1 (en)	2006-04-05	2013-06-26	Novartis AG	Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
AR060358A1 (es) *	2006-04-06	2008-06-11	Novartis Vaccines & Diagnostic	Quinazolinas para la inhibicion de pdk 1
MX2008013430A (es)	2006-04-19	2009-01-26	Novartis Vaccines & Diagnostic	Compuestos de indazol y metodos para la inhibición de cdc7.
PE20080695A1 (es)	2006-04-27	2008-06-28	Banyu Pharma Co Ltd	Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
CN101443002B (zh)	2006-05-09	2012-03-21	诺瓦提斯公司	包含铁螯合剂和抗肿瘤药的组合及其用途
CN101443009A (zh) *	2006-05-18	2009-05-27	卫材R&D管理有限公司	针对甲状腺癌的抗肿瘤剂
EP2038654A4 (en) *	2006-06-12	2010-08-11	Bipar Sciences Inc	METHOD FOR THE TREATMENT OF DISEASES WITH PARP INHIBITORS
US20100279327A1 (en) *	2006-06-12	2010-11-04	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
WO2008001956A1 (fr) *	2006-06-29	2008-01-03	Eisai R & D Management Co., Ltd.	Agent thérapeutique contre la fibrose hépatique
AU2007274284B2 (en)	2006-07-13	2012-04-26	Janssen Pharmaceutica N.V.	Mtki quinazoline derivatives
US8217177B2 (en)	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
PE20121506A1 (es)	2006-07-14	2012-11-26	Amgen Inc	Compuestos triazolopiridinas como inhibidores de c-met
RS53263B (en)	2006-08-14	2014-08-29	Xencor Inc.	CD19 OPTIMIZED ANTIBODY
WO2008026748A1 (fr)	2006-08-28	2008-03-06	Eisai R & D Management Co., Ltd.	Agent antitumoral pour cancer gastrique non différencié
JP2008081492A (ja)	2006-08-31	2008-04-10	Banyu Pharmaceut Co Ltd	オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
CN101522609A (zh) *	2006-09-05	2009-09-02	彼帕科学公司	癌症的治疗
EP2061479A4 (en) *	2006-09-05	2010-08-04	Bipar Sciences Inc	FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH
CA2662587C (en) *	2006-09-11	2013-08-06	Curis, Inc.	Quinazoline based egfr inhibitors
ATE522625T1 (de)	2006-09-12	2011-09-15	Genentech Inc	Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker
EP2068880B1 (en)	2006-09-18	2012-04-11	Boehringer Ingelheim International GmbH	Method for treating cancer harboring egfr mutations
CA2664378A1 (en)	2006-09-29	2008-04-03	Novartis Ag	Pyrazolopyrimidines as pi3k lipid kinase inhibitors
US8916552B2 (en)	2006-10-12	2014-12-23	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008044045A1 (en)	2006-10-12	2008-04-17	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008046242A1 (fr) *	2006-10-16	2008-04-24	Institute Of Mataria Medica, Chinese Academy Of Medical Sciences	Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations
US8586621B2 (en)	2006-10-27	2013-11-19	Michael A. Zeligs	Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
JP2010507625A (ja) *	2006-10-27	2010-03-11	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	脳ガンの処置又は予防のためのｍｔキナーゼ阻害剤の使用
US7851623B2 (en)	2006-11-02	2010-12-14	Astrazeneca Ab	Chemical process
EP1921070A1 (de)	2006-11-10	2008-05-14	Boehringer Ingelheim Pharma GmbH & Co. KG	Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
BRPI0720032A2 (pt) *	2006-12-13	2013-12-17	Gilead Sciences Inc	Composto e sais farmaceuticamente aceitáveis dos mesmos, processo, formulação de aerossol, método para a prevenção e tratamento de inflamação pulmonar ou broncoconstrição, e, uso de um composto.
CA2672438A1 (en)	2006-12-20	2008-07-03	Amgen Inc.	Substituted heterocycles and methods of use
US7977336B2 (en)	2006-12-28	2011-07-12	Banyu Pharmaceutical Co. Ltd	Aminopyrimidine derivatives as PLK1 inhibitors
EP2118069B1 (en)	2007-01-09	2014-01-01	Amgen Inc.	Bis-aryl amide derivatives useful for the treatment of cancer
AU2008211952B2 (en)	2007-01-29	2012-07-19	Eisai R & D Management Co., Ltd.	Composition for treatment of undifferentiated-type of gastric cancer
AU2008212999A1 (en)	2007-02-06	2008-08-14	Boehringer Ingelheim International Gmbh	Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
EP2120900A2 (en)	2007-02-15	2009-11-25	Novartis AG	Combination of lbh589 with other therapeutic agents for treating cancer
EP2114898A2 (en)	2007-02-16	2009-11-11	Amgen Inc.	Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
PE20090681A1 (es)	2007-03-02	2009-06-10	Genentech Inc	Prediccion de respuesta a un inhibidor her
US20100292209A1 (en) *	2007-03-30	2010-11-18	Massachusetts Institute Of Technology	Methods for identifying compounds that modulate neurotrophic factor signaling
JP2010524909A (ja)	2007-04-16	2010-07-22	シプラ・リミテッド	ゲフィチニブの製造方法
DK2176298T3 (en)	2007-05-30	2018-02-12	Xencor Inc	Methods and compositions for inhibiting CD32B-expressing cells
WO2008154249A2 (en)	2007-06-08	2008-12-18	Genentech, Inc.	Gene expression markers of tumor resistance to her2 inhibitor treatment
CA2687909C (en) *	2007-06-21	2015-09-15	Janssen Pharmaceutica Nv	Indolin-2-ones and aza-indolin-2-ones
EP2185562B1 (en)	2007-07-27	2015-12-02	Janssen Pharmaceutica, N.V.	Pyrrolopyrimidines useful for the treatment of proliferative diseases
JP5749009B2 (ja) *	2007-08-13	2015-07-15	バスジーンセラピューティクス，インコーポレイテッドＶａｓｇｅｎｅｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤
DK2188313T3 (en)	2007-08-21	2017-12-11	Amgen Inc	HUMAN C-FMS ANTI-BINDING PROTEINS
WO2009035718A1 (en) *	2007-09-10	2009-03-19	Curis, Inc.	Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
US8022216B2 (en)	2007-10-17	2011-09-20	Wyeth Llc	Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2703720A1 (en) *	2007-10-19	2009-04-23	Albert Einstein College Of Medicine Of Yeshiva University	Improved antitumoral treatments
EP2211854A4 (en) *	2007-10-19	2011-01-12	Bipar Sciences Inc	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER USING BENZOPYRONE-TYPE PARP INHIBITORS
WO2009054332A1 (ja)	2007-10-23	2009-04-30	Banyu Pharmaceutical Co., Ltd.	ピリドン置換ジヒドロピラゾロピリミジノン誘導体
WO2009057139A2 (en)	2007-10-29	2009-05-07	Natco Pharma Limited	Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
EP2218712B1 (en)	2007-11-09	2015-07-01	Eisai R&D Management Co., Ltd.	Combination of anti-angiogenic substance and anti-tumor platinum complex
US7732491B2 (en) *	2007-11-12	2010-06-08	Bipar Sciences, Inc.	Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
EP2217244A4 (en) *	2007-11-12	2011-08-31	Bipar Sciences Inc	TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES
WO2009067543A2 (en) *	2007-11-19	2009-05-28	The Regents Of The University Of Colorado	Treatment of histone deacetylase mediated disorders
AR069393A1 (es)	2007-11-21	2010-01-20	Imclone Systems Inc	Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
AU2008333786A1 (en) *	2007-12-07	2009-06-11	Bipar Sciences, Inc.	Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
CN101952282A (zh)	2007-12-20	2011-01-19	诺瓦提斯公司	用作pi 3激酶抑制剂的噻唑衍生物
BRPI0822012A2 (pt) *	2008-01-18	2015-07-21	Natco Pharma Ltd	Derivados de quinazolina de 6,7-dialcóxi úteis para o tratamento de distúrbios relacionados com câncer
EP2242493B1 (en)	2008-01-22	2013-06-05	Concert Pharmaceuticals Inc.	Derivatives of gefitinib
JP5399926B2 (ja) *	2008-01-29	2014-01-29	エーザイ・アール・アンド・ディー・マネジメント株式会社	血管阻害物質とタキサンとの併用
AU2009209541A1 (en) *	2008-01-30	2009-08-06	Pharma Mar, S.A.	Improved antitumoral treatments
TWI472339B (zh)	2008-01-30	2015-02-11	Genentech Inc	包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
CA2711582A1 (en)	2008-02-07	2009-08-13	Boehringer Ingelheim International Gmbh	Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof
WO2009109605A1 (en) *	2008-03-05	2009-09-11	Novartis Ag	Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
WO2009109649A1 (en) *	2008-03-07	2009-09-11	Pharma Mar, S.A.	Improved antitumoral treatments
KR101673621B1 (ko)	2008-03-24	2016-11-07	노파르티스 아게	아릴술폰아미드-계 매트릭스 메탈로프로테아제 억제제
CN101544609A (zh)	2008-03-25	2009-09-30	上海艾力斯医药科技有限公司	4-苯胺喹唑啉衍生物的结晶形式
EP2628726A1 (en)	2008-03-26	2013-08-21	Novartis AG	Hydroxamate-based inhibitors of deacetylases b
JP5739802B2 (ja)	2008-05-13	2015-06-24	アストラゼネカアクチボラグ	４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
NZ597292A (en)	2008-05-14	2013-06-28	Genomic Health Inc	Use of PTP4A3 to predict a patient's response to treatment with an EGF receptor inhibitor
CN101584696A (zh)	2008-05-21	2009-11-25	上海艾力斯医药科技有限公司	包含喹唑啉衍生物的组合物及制备方法、用途
CA2725598C (en)	2008-06-17	2013-10-08	Wyeth Llc	Antineoplastic combinations containing hki-272 and vinorelbine
DE102008031040A1 (de)	2008-06-30	2009-12-31	Alexander Priv.-Doz. Dr. Dömling	Iressa zur Anwendung in der Organtransplantation
NZ590464A (en)	2008-08-04	2012-10-26	Wyeth Llc	Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine
JP5539351B2 (ja)	2008-08-08	2014-07-02	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
CN101367793B (zh) *	2008-09-26	2013-09-11	中国科学院广州生物医药与健康研究院	一种具有抗肿瘤活性的氨基喹唑啉衍生物及其盐类
ES2704986T3 (es)	2008-10-16	2019-03-21	Celator Pharmaceuticals Inc	Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab
US8710104B2 (en)	2008-11-07	2014-04-29	Triact Therapeutics, Inc.	Catecholic butanes and use thereof for cancer therapy
EP2370082A4 (en) *	2008-12-01	2012-05-30	Univ Central Florida Res Found	FOR BELLY CANCER CELLS CYTOTOXIC DRUG COMPOSITION
RU2011129230A (ru)	2008-12-18	2013-01-27	Новартис Аг	Новая полиморфная форма 1-[4-[1-(4-циклогексил-3-трифторметилбензилоксиимино)этил]-2-этилбензил]азетидин-3-карбоновой кислоты
UY32330A (es)	2008-12-18	2010-07-30	Novartis Ag	Novedosa forma de sal de ácido 1-(4-{1-[e-4-ciclohexil-3-trifluoro-metil-benciloxi-imino]-etil}-2-etil-bencil)-azetidin-3-carboxílico, formas polimórficas, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones
CN103204794A (zh)	2008-12-18	2013-07-17	诺瓦提斯公司	新的盐
TWI577664B (zh)	2009-01-16	2017-04-11	艾克塞里克斯公司	Ｎ-（４-｛〔６，７-雙（甲氧基）喹啉-４-基〕氧基｝苯基）-ｎ’-（４-氟苯基）環丙烷-１，１-二甲醯胺蘋果酸鹽、包含其之醫藥組合物及其用途
WO2010083617A1 (en)	2009-01-21	2010-07-29	Oncalis Ag	Pyrazolopyrimidines as protein kinase inhibitors
TW201031406A (en)	2009-01-29	2010-09-01	Novartis Ag	Substituted benzimidazoles for the treatment of astrocytomas
US20120189641A1 (en)	2009-02-25	2012-07-26	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
CA2750716A1 (en)	2009-02-25	2010-09-02	Msd K.K.	Pyrimidopyrimidoindazole derivative
US20110171124A1 (en)	2009-02-26	2011-07-14	Osi Pharmaceuticals, Inc.	In situ methods for monitoring the EMT status of tumor cells in vivo
EP2401613A2 (en)	2009-02-27	2012-01-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en)	2009-02-27	2014-02-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8481503B2 (en)	2009-03-06	2013-07-09	Merck Sharp & Dohme Corp.	Combination cancer therapy with an AKT inhibitor and other anticancer agents
JP2012520893A (ja)	2009-03-18	2012-09-10	オーエスアイ・ファーマシューティカルズ，エルエルシー	Ｅｇｆｒ阻害薬及びｉｇｆ−１ｒ阻害剤の投与を含む組み合わせ癌治療
TW201544123A (zh)	2009-03-20	2015-12-01	Genentech Inc	抗-ｈｅｒ抗體
DK3000467T3 (da)	2009-04-06	2023-03-27	Wyeth Llc	Behandling med neratinib mod brystkræft
US8530492B2 (en)	2009-04-17	2013-09-10	Nektar Therapeutics	Oligomer-protein tyrosine kinase inhibitor conjugates
UA105794C2 (uk)	2009-06-26	2014-06-25	Новартіс Аг	1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
EP2451445B1 (en)	2009-07-06	2019-04-03	Boehringer Ingelheim International GmbH	Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US9050341B2 (en) *	2009-07-14	2015-06-09	Natco Pharma Limited	Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
US9345661B2 (en)	2009-07-31	2016-05-24	Genentech, Inc.	Subcutaneous anti-HER2 antibody formulations and uses thereof
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
AU2010283806A1 (en)	2009-08-12	2012-03-01	Novartis Ag	Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
MX2012002066A (es)	2009-08-17	2012-03-29	Intellikine Inc	Compuestos heterociclicos y usos de los mismos.
JP5775871B2 (ja)	2009-08-20	2015-09-09	ノバルティスアーゲー	ヘテロ環式オキシム化合物
EP2470502A1 (en)	2009-08-26	2012-07-04	Novartis AG	Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
IN2012DN02139A (xx)	2009-09-10	2015-08-07	Novartis Ag
EP2494070A2 (en)	2009-10-30	2012-09-05	Bristol-Myers Squibb Company	Methods for treating cancer in patients having igf-1r inhibitor resistance
AU2010317167B2 (en)	2009-11-04	2012-11-29	Novartis Ag	Heterocyclic sulfonamide derivatives useful as MEK inhibitors
RU2012124093A (ru)	2009-11-12	2013-12-20	Дженентек, Инк.	Способ увеличения плотности дендритных шипиков
WO2011058164A1 (en)	2009-11-13	2011-05-19	Pangaea Biotech, S.A.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
JP6220126B2 (ja)	2009-11-23	2017-10-25	セルリアン・ファーマ・インコーポレイテッド	治療的送達のためのシクロデキストリンに基づく重合体
US20120289501A1 (en)	2009-11-25	2012-11-15	Novartis Ag	Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
CA2781682A1 (en)	2009-12-04	2011-06-09	Genentech, Inc.	Multispecific antibodies, antibody analogs, compositions, and methods
EP2509964B1 (en)	2009-12-08	2014-04-30	Novartis AG	Heterocyclic sulfonamide derivatives
CU24130B1 (es)	2009-12-22	2015-09-29	Novartis Ag	Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en)	2009-12-22	2013-05-14	Novartis Ag	Substituted isoquinolinones and quinazolinones
CA2781578A1 (en)	2010-01-12	2011-07-21	F. Hoffmann-La Roche Ag	Tricyclic heterocyclic compounds, compositions and methods of use thereof
US20110178287A1 (en)	2010-01-19	2011-07-21	Cerulean Pharma Inc.	Cyclodextrin-based polymers for therapeutic delivery
CN102146060B (zh) *	2010-02-09	2013-07-03	陕西师范大学	制备吉非替尼及其中间体的方法
US9556249B2 (en)	2010-02-18	2017-01-31	Genentech, Inc.	Neuregulin antagonists and use thereof in treating cancer
AU2011222867B2 (en)	2010-03-04	2014-03-06	Annika Algars	Method for selecting patients for treatment with an EGFR inhibitor
MX2012010265A (es)	2010-03-17	2012-10-01	Hoffmann La Roche	Compuestos de imidazopiridina, composiciones y metodos de uso.
US20110237686A1 (en)	2010-03-26	2011-09-29	Cerulean Pharma Inc	Formulations and methods of use
RU2012145183A (ru)	2010-03-29	2014-05-10	Займворкс, Инк.	Антитела с повышенной или пониженной эффекторной функцией
TWI406853B (zh) *	2010-04-07	2013-09-01	Dev Center Biotechnology	Ｅｇｆｒ與ｖｅｇｆｒ－２雙重抑制劑及其用途與製法
JP2013528787A (ja)	2010-04-16	2013-07-11	ジェネンテック，インコーポレイテッド	Ｐｉ３ｋ／ａｋｔキナーゼ経路インヒビターの効果の予測バイオマーカーとしてのｆｏｘ０３ａ
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
EP2582680A1 (en)	2010-06-17	2013-04-24	Novartis AG	Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
JP2013532149A (ja)	2010-06-17	2013-08-15	ノバルティスアーゲー	ピペリジニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体
WO2011161217A2 (en)	2010-06-23	2011-12-29	Palacký University in Olomouc	Targeting of vegfr2
ES2573515T3 (es)	2010-06-25	2016-06-08	Eisai R&D Management Co., Ltd.	Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
UA112517C2 (uk)	2010-07-06	2016-09-26	Новартіс Аг	Тетрагідропіридопіримідинові похідні
AR082418A1 (es)	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
DK2612151T3 (en)	2010-08-31	2017-10-02	Genentech Inc	BIOMARKETS AND METHODS OF TREATMENT
RU2013114352A (ru)	2010-09-15	2014-10-20	Ф. Хоффманн-Ля Рош Аг	Азабензотиазолы, композиции и способы применения
US8946260B2 (en)	2010-09-16	2015-02-03	Novartis Ag	17α-hydroxylase/C17,20-lyase inhibitors
SG188548A1 (en)	2010-09-22	2013-04-30	Arena Pharm Inc	Modulators of the gpr119 receptor and the treatment of disorders related thereto
US9309322B2 (en)	2010-11-12	2016-04-12	Scott & White Healthcare (Swh)	Antibodies to tumor endothelial marker 8
MX2013005445A (es)	2010-11-19	2013-07-29	Hoffmann La Roche	Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
EP2643351A1 (en)	2010-11-24	2013-10-02	Glaxo Group Limited	Multispecific antigen binding proteins targeting hgf
BR112013015449A2 (pt)	2010-12-21	2016-09-20	Novartis Ag	compostos de bi-heteroarila como inibidores de vps23
EP2468883A1 (en)	2010-12-22	2012-06-27	Pangaea Biotech S.L.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
WO2012085176A1 (en)	2010-12-23	2012-06-28	F. Hoffmann-La Roche Ag	Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
US9134297B2 (en)	2011-01-11	2015-09-15	Icahn School Of Medicine At Mount Sinai	Method and compositions for treating cancer and related methods
UY33883A (es)	2011-01-31	2012-08-31	Novartis Ag	Novedosos derivados heterocíclicos
US20130324526A1 (en)	2011-02-10	2013-12-05	Novartis Ag	[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja)	2011-02-23	2015-11-10	インテリカイン，エルエルシー	複素環化合物およびその使用
EP2492688A1 (en)	2011-02-23	2012-08-29	Pangaea Biotech, S.A.	Molecular biomarkers for predicting response to antitumor treatment in lung cancer
KR102061743B1 (ko)	2011-03-04	2020-01-03	뉴젠 세러퓨틱스 인코포레이티드	알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
WO2012120469A1 (en)	2011-03-08	2012-09-13	Novartis Ag	Fluorophenyl bicyclic heteroaryl compounds
AU2012225246B2 (en)	2011-03-10	2016-01-21	Omeros Corporation	Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
EP2685980B1 (en)	2011-03-17	2017-12-06	The Trustees Of The University Of Pennsylvania	Methods and use of bifunctional enzyme-building clamp-shaped molecules
WO2012125904A1 (en)	2011-03-17	2012-09-20	The Trustees Of The University Of Pennsylvania	Mutation mimicking compounds that bind to the kinase domain of egfr
WO2012129145A1 (en)	2011-03-18	2012-09-27	OSI Pharmaceuticals, LLC	Nscle combination therapy
CA2830516C (en)	2011-03-23	2017-01-24	Amgen Inc.	Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US8962650B2 (en)	2011-04-18	2015-02-24	Eisai R&D Management Co., Ltd.	Therapeutic agent for tumor
WO2012149014A1 (en)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
GB201106870D0 (en)	2011-04-26	2011-06-01	Univ Belfast	Marker
KR20140025492A (ko)	2011-04-28	2014-03-04	노파르티스 아게	17α-히드록실라제/C17,20-리아제 억제제
CN102918029B (zh)	2011-05-17	2015-06-17	江苏康缘药业股份有限公司	4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
JP6038128B2 (ja)	2011-06-03	2016-12-07	エーザイ・アール・アンド・ディー・マネジメント株式会社	レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
EA201391820A1 (ru)	2011-06-09	2014-12-30	Новартис Аг	Гетероциклические сульфонамидные производные
US8859586B2 (en)	2011-06-20	2014-10-14	Novartis Ag	Cyclohexyl isoquinolinone compounds
US8859535B2 (en)	2011-06-20	2014-10-14	Novartis Ag	Hydroxy substituted isoquinolinone derivatives
EA201490164A1 (ru)	2011-06-27	2014-04-30	Новартис Аг	Твердые формы и соли производных тетрагидропиридопиримидина
KR20140045440A (ko)	2011-06-30	2014-04-16	제넨테크, 인크.	항-c-met 항체 제제
WO2013007765A1 (en)	2011-07-13	2013-01-17	F. Hoffmann-La Roche Ag	Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013007768A1 (en)	2011-07-13	2013-01-17	F. Hoffmann-La Roche Ag	Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
CA2843499A1 (en)	2011-08-12	2013-02-21	F. Hoffmann-La Roche Ag	Indazole compounds, compositions and methods of use
EP3783028A1 (en)	2011-08-12	2021-02-24	Omeros Corporation	Anti-fzd10 monoclonal antibodies and methods for their use
WO2013025939A2 (en)	2011-08-16	2013-02-21	Indiana University Research And Technology Corporation	Compounds and methods for treating cancer by inhibiting the urokinase receptor
CN103890007A (zh)	2011-08-17	2014-06-25	霍夫曼-拉罗奇有限公司	神经调节蛋白抗体及其用途
EP2751285B2 (en)	2011-08-31	2020-04-01	Genentech, Inc.	Method for sensitivity testing of a tumour for a egfr kinase inhibitor
WO2013038362A1 (en)	2011-09-15	2013-03-21	Novartis Ag	6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
BR112014006643A2 (pt)	2011-09-20	2017-04-04	Hoffmann La Roche	compostos de imidazopiridina, composições e métodos de uso dos mesmos
CN103012290B (zh) *	2011-09-28	2015-05-13	齐鲁制药有限公司	一种高纯度吉非替尼的制备方法
KR20140066783A (ko)	2011-09-30	2014-06-02	제넨테크, 인크.	종양 또는 종양 세포에서의 상피 또는 중간엽 표현형 및 egfr 키나제 억제제에 대한 반응의 진단 메틸화 마커
EP2766497A1 (en)	2011-10-13	2014-08-20	Bristol-Myers Squibb Company	Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
MX340452B (es)	2011-10-28	2016-07-08	Novartis Ag	Novedosos derivados de purina y su uso en el tratamiento de enfermedades.
CN103102345B (zh) *	2011-11-14	2015-06-03	广东东阳光药业有限公司	氨基喹唑啉类衍生物及其盐和使用方法
CN103102342B (zh) *	2011-11-14	2014-10-29	广东东阳光药业有限公司	氨基喹唑啉类衍生物及其盐和使用方法
AR092289A1 (es)	2011-11-14	2015-04-15	Sunshine Lake Pharma Co Ltd	Derivados de aminoquinazolina y sus sales y metodos de uso
US8969341B2 (en)	2011-11-29	2015-03-03	Novartis Ag	Pyrazolopyrrolidine compounds
WO2013081645A2 (en)	2011-11-30	2013-06-06	Genentech, Inc.	Erbb3 mutations in cancer
US9408885B2 (en)	2011-12-01	2016-08-09	Vib Vzw	Combinations of therapeutic agents for treating melanoma
CN103130729B (zh) *	2011-12-05	2015-07-15	齐鲁制药有限公司	一种4-氯代-7-甲氧基喹唑啉-6-醇乙酸酯的制备方法
CN103172576B (zh) *	2011-12-21	2015-08-05	沈阳药科大学	吉非替尼的苹果酸加成盐及其制备和应用
SI2794600T1 (en)	2011-12-22	2018-03-30	Novartis Ag	2,3-Dihydro-benzo (1,4) oxazine derivatives and related compounds as phosphoinositide-3 kinase inhibitors (PI3K) for the treatment, e.g. rheumatoid arthritis
WO2013093850A1 (en)	2011-12-22	2013-06-27	Novartis Ag	Quinoline derivatives
BR112014015274A8 (pt)	2011-12-23	2017-06-13	Novartis Ag	compostos e composições para inibição da interação de bcl2 com parceiros de ligação
CA2859869A1 (en)	2011-12-23	2013-06-27	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
US20130178520A1 (en)	2011-12-23	2013-07-11	Duke University	Methods of treatment using arylcyclopropylamine compounds
AU2012355624A1 (en)	2011-12-23	2014-07-17	Novartis Ag	Compounds for inhibiting the interaction of BCL2 with binding partners
BR112014015308A2 (pt)	2011-12-23	2017-06-13	Novartis Ag	compostos para inibição da interação de bcl2 com contrapartes de ligação
WO2013096051A1 (en)	2011-12-23	2013-06-27	Novartis Ag	Compounds for inhibiting the interaction of bcl2 with binding partners
UY34591A (es)	2012-01-26	2013-09-02	Novartis Ag	Compuestos de imidazopirrolidinona
EP2809805A1 (en)	2012-01-31	2014-12-10	SmithKline Beecham (Cork) Limited	Method of treating cancer
US20140170159A9 (en)	2012-03-08	2014-06-19	Ge Wei	Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
AR090263A1 (es)	2012-03-08	2014-10-29	Hoffmann La Roche	Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US9193718B2 (en)	2012-03-26	2015-11-24	Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences	Quinazoline derivative and application thereof
RU2014136886A (ru)	2012-03-27	2016-05-20	Дженентек, Инк.	Диагностика и виды лечения, связанные с ингибиторами her3
CN104245701A (zh)	2012-04-03	2014-12-24	诺华有限公司	有酪氨酸激酶抑制剂的组合产品和其应用
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
AU2013263043B2 (en)	2012-05-16	2016-06-16	Novartis Ag	Dosage regimen for a PI-3 kinase inhibitor
US9365576B2 (en)	2012-05-24	2016-06-14	Novartis Ag	Pyrrolopyrrolidinone compounds
KR101457453B1 (ko) *	2012-05-31	2014-11-04	주식회사 종근당	게피티닙의 제조방법 및 이의 제조에 사용되는 중간체
WO2013188763A1 (en)	2012-06-15	2013-12-19	The Brigham And Women's Hospital, Inc.	Compositions for treating cancer and methods for making the same
WO2013190089A1 (en)	2012-06-21	2013-12-27	Pangaea Biotech, S.L.	Molecular biomarkers for predicting outcome in lung cancer
WO2014016848A2 (en)	2012-07-24	2014-01-30	Laurus Labs Private Limited	Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
US9738643B2 (en)	2012-08-06	2017-08-22	Duke University	Substituted indazoles for targeting Hsp90
US9505749B2 (en)	2012-08-29	2016-11-29	Amgen Inc.	Quinazolinone compounds and derivatives thereof
WO2014071402A1 (en)	2012-11-05	2014-05-08	Dana-Farber Cancer Institute, Inc.	Xbp1, cd138, and cs1, pharmaceutical compositions that include the peptides, and methods of using such petides and compositions
TW201422625A (zh)	2012-11-26	2014-06-16	Novartis Ag	二氫－吡啶并－□衍生物之固體形式
KR20150098605A (ko)	2012-12-21	2015-08-28	에자이 알앤드디 매니지먼트 가부시키가이샤	퀴놀린 유도체의 비정질 형태 및 그의 제조방법
CN103073509A (zh) *	2012-12-31	2013-05-01	广东先强药业有限公司	一类喹唑啉衍生物的制备方法
CN103910690A (zh) *	2013-01-06	2014-07-09	上海科胜药物研发有限公司	一种吉非替尼新晶型及其制备方法
WO2014108858A1 (en)	2013-01-10	2014-07-17	Glaxosmithkline Intellectual Property (No.2) Limited	Fatty acid synthase inhibitors
EP2948451B1 (en)	2013-01-22	2017-07-12	Novartis AG	Substituted purinone compounds
WO2014115080A1 (en)	2013-01-22	2014-07-31	Novartis Ag	Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
CN104968200B (zh)	2013-02-01	2018-03-06	维尔斯达医疗公司	具有抗炎、抗真菌、抗寄生物和抗癌活性的胺化合物
EP3626741A1 (en)	2013-02-20	2020-03-25	The Trustees Of The University Of Pennsylvania	Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2014128612A1 (en)	2013-02-20	2014-08-28	Novartis Ag	Quinazolin-4-one derivatives
CN104994879A (zh)	2013-02-22	2015-10-21	霍夫曼-拉罗奇有限公司	治疗癌症和预防药物抗性的方法
AU2014223548A1 (en)	2013-02-26	2015-10-15	Triact Therapeutics, Inc.	Cancer therapy
US9468681B2 (en)	2013-03-01	2016-10-18	California Institute Of Technology	Targeted nanoparticles
JP2016510751A (ja)	2013-03-06	2016-04-11	ジェネンテック，インコーポレイテッド	抗がん剤耐性を治療及び予防する方法
LT2964638T (lt)	2013-03-06	2017-12-27	Astrazeneca Ab	Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
US10035801B2 (en)	2013-03-13	2018-07-31	Genentech, Inc.	Pyrazolo compounds and uses thereof
BR112015022604A2 (pt)	2013-03-14	2017-10-24	Genentech Inc	usos de um modulador de modificador de cromatina e um antagonista de egfr
CA2903480A1 (en)	2013-03-14	2014-09-25	Genentech, Inc.	Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
KR102334260B1 (ko)	2013-03-14	2021-12-02	스미토모 다이니폰 파마 온콜로지, 인크.	Ｊａｋ2 및 ａｌｋ2 억제제 및 이들의 사용 방법
CN105246482A (zh)	2013-03-15	2016-01-13	因特利凯有限责任公司	激酶抑制剂的组合及其用途
EP2968537A1 (en)	2013-03-15	2016-01-20	Genentech, Inc.	Methods of treating cancer and preventing cancer drug resistance
EP2976085A1 (en)	2013-03-21	2016-01-27	INSERM - Institut National de la Santé et de la Recherche Médicale	Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
WO2014147631A1 (en)	2013-03-22	2014-09-25	Natco Pharma Limited	Formulation comprising gefitinib as oral suspension
WO2014155268A2 (en)	2013-03-25	2014-10-02	Novartis Ag	Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
CN105264380B (zh)	2013-05-14	2017-09-05	卫材R&D管理有限公司	用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
US20150018376A1 (en)	2013-05-17	2015-01-15	Novartis Ag	Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
CN103304491A (zh) *	2013-06-17	2013-09-18	连云港盛和生物科技有限公司	一种吉非替尼的制备方法
KR20150001936A (ko) *	2013-06-28	2015-01-07	제일약품주식회사	게피티닙의 신규한 결정형 및 이의 제조방법
UY35675A (es)	2013-07-24	2015-02-27	Novartis Ag	Derivados sustituidos de quinazolin-4-ona
EP3027623A4 (en) *	2013-08-02	2017-03-01	Ignyta, Inc.	METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS
US9227969B2 (en)	2013-08-14	2016-01-05	Novartis Ag	Compounds and compositions as inhibitors of MEK
WO2015022664A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
WO2015022663A1 (en)	2013-08-14	2015-02-19	Novartis Ag	Compounds and compositions as inhibitors of mek
RU2016112568A (ru)	2013-09-05	2017-10-06	Дженентек, Инк.	Антипролиферативные соединения
CA2923667A1 (en)	2013-09-09	2015-03-12	Triact Therapeutics, Inc.	Cancer therapy
MX2016003256A (es)	2013-09-12	2016-06-07	Halozyme Inc	Anticuerpos modificados del receptor de factor de crecimiento anti-epidermico y metodos de uso de los mismos.
RU2675105C9 (ru)	2013-09-22	2019-01-09	Саншайн Лейк Фарма Ко., Лтд.	Замещенные аминопиримидиновые соединения и способы их использования
CN104513253A (zh) *	2013-10-01	2015-04-15	南京波尔泰药业科技有限公司	用于治疗增殖性疾病的大环化合物
TW201605857A (zh)	2013-10-03	2016-02-16	赫孚孟拉羅股份公司	Ｃｄｋ８之醫療性抑制劑及其用途
KR20160070136A (ko)	2013-10-18	2016-06-17	제넨테크, 인크.	항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
WO2015084804A1 (en)	2013-12-03	2015-06-11	Novartis Ag	Combination of mdm2 inhibitor and braf inhibitor and their use
RU2680246C1 (ru)	2013-12-06	2019-02-19	Новартис Аг	Схема приема для селективного по альфа-изоформе ингибитора фосфатидилинозитол-3-киназы
CA2934028A1 (en)	2013-12-17	2015-06-25	Genentech, Inc.	Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
NZ720515A (en)	2013-12-17	2022-12-23	Genentech Inc	Methods of treating cancers using pd-1 axis binding antagonists and taxanes
US9242965B2 (en)	2013-12-31	2016-01-26	Boehringer Ingelheim International Gmbh	Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2015128837A1 (en)	2014-02-26	2015-09-03	Glaxosmithkline Intellectual Property (No.2) Limited	Methods of treating cancer patients responding to ezh2 inhibitor gsk126
MA39776A (fr)	2014-03-24	2017-02-01	Hoffmann La Roche	Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
WO2015148714A1 (en)	2014-03-25	2015-10-01	Duke University	Heat shock protein 70 (hsp-70) receptor ligands
WO2015145388A2 (en)	2014-03-27	2015-10-01	Novartis Ag	Methods of treating colorectal cancers harboring upstream wnt pathway mutations
US9394281B2 (en)	2014-03-28	2016-07-19	Calitor Sciences, Llc	Substituted heteroaryl compounds and methods of use
MA51552A (fr)	2014-03-31	2021-03-24	Hoffmann La Roche	Anticorps anti-ox40 et procédés d'utilisation
RU2016142476A (ru)	2014-03-31	2018-05-07	Дженентек, Инк.	Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
AU2015241198A1 (en)	2014-04-03	2016-11-17	Invictus Oncology Pvt. Ltd.	Supramolecular combinatorial therapeutics
US20170027940A1 (en)	2014-04-10	2017-02-02	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015170345A1 (en)	2014-05-09	2015-11-12	Council Of Scientific & Industrial Research	Pharmaceutical cocrystals of gefitinib
RU2577518C2 (ru) *	2014-06-02	2016-03-20	Олег Ростиславович Михайлов	КРИСТАЛЛИЧЕСКАЯ БЕЗВОДНАЯ γ-МОДИФИКАЦИЯ 4-(3'-ХЛОР-4'-ФТОРАНИЛИНО)-7-МЕТОКСИ-6-(3-МОРФОЛИНОПРОПОКСИ)ХИНАЗОЛИНА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ
JP6276894B2 (ja) *	2014-06-10	2018-02-07	サイノファーム（チャンシュー）ファーマシューティカルズリミテッド	キナゾリン誘導体作製方法
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
JP6526789B2 (ja)	2014-07-31	2019-06-05	ノバルティスアーゲー	組み合わせ療法
HRP20221047T1 (hr)	2014-08-28	2022-11-11	Eisai R&D Management Co., Ltd.	Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
WO2016036873A1 (en)	2014-09-05	2016-03-10	Genentech, Inc.	Therapeutic compounds and uses thereof
TWI567063B (zh) *	2014-09-05	2017-01-21	國立交通大學	用於促進癌細胞凋亡的化合物、其醫藥組成物及其用途
EP3193866A1 (en)	2014-09-19	2017-07-26	Genentech, Inc.	Use of cbp/ep300 and bet inhibitors for treatment of cancer
CN107912040B (zh)	2014-10-10	2021-04-06	基因泰克公司	作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
EP3206717B1 (en)	2014-10-17	2020-11-25	Novartis AG	Combination of ceritinib with an egfr inhibitor
CN106796235B (zh)	2014-11-03	2021-01-29	豪夫迈·罗氏有限公司	用于检测t细胞免疫子集的测定法及其使用方法
CN107109484B (zh)	2014-11-03	2021-12-14	豪夫迈·罗氏有限公司	用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
CN107073126A (zh)	2014-11-06	2017-08-18	豪夫迈·罗氏有限公司	包含ox40结合激动剂和tigit抑制剂的组合疗法
EP3218376B1 (en)	2014-11-10	2019-12-25	Genentech, Inc.	Bromodomain inhibitors and uses thereof
MA40940A (fr)	2014-11-10	2017-09-19	Constellation Pharmaceuticals Inc	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40943A (fr)	2014-11-10	2017-09-19	Constellation Pharmaceuticals Inc	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
BR112017010198A2 (pt)	2014-11-17	2017-12-26	Genentech Inc	terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
WO2016086200A1 (en)	2014-11-27	2016-06-02	Genentech, Inc.	4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
EP3228650B1 (en)	2014-12-04	2022-03-09	Delta-Fly Pharma, Inc.	Novel peg derivative
EP3233064A1 (en)	2014-12-19	2017-10-25	Synthon BV	Pharmaceutical composition comprising gefifinib
JP2018508183A (ja)	2014-12-23	2018-03-29	ジェネンテック，インコーポレイテッド	化学療法耐性癌を治療及び診断する組成物及び方法
CN107223163A (zh)	2014-12-24	2017-09-29	豪夫迈·罗氏有限公司	用于膀胱癌症的治疗，诊断和预后方法
JP2018503373A (ja)	2014-12-30	2018-02-08	ジェネンテック，インコーポレイテッド	がんの予後診断及び治療のための方法及び組成物
MX2017008925A (es)	2015-01-06	2017-10-11	Arena Pharm Inc	Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3242934B1 (en)	2015-01-08	2021-08-18	The Board of Trustees of the Leland Stanford Junior University	Factors and cells that provide for induction of bone, bone marrow, and cartilage
CN107406418B (zh)	2015-01-09	2021-10-29	基因泰克公司	4,5-二氢咪唑衍生物及其作为组蛋白脱甲基酶(kdm2b)抑制剂的用途
JP6659703B2 (ja)	2015-01-09	2020-03-04	ジェネンテック，インコーポレイテッド	ピリダジノン誘導体および癌の処置におけるそれらの使用
JP6855379B2 (ja)	2015-01-09	2021-04-07	ジェネンテック，インコーポレイテッド	癌の処置のためのヒストンデメチラーゼｋｄｍ２ｂのインヒビターとしての（ピペリジン−３−イル）（ナフタレン−２−イル）メタノン誘導体および関連化合物
MA41414A (fr)	2015-01-28	2017-12-05	Centre Nat Rech Scient	Protéines de liaison agonistes d' icos
KR101635724B1 (ko) *	2015-01-28	2016-07-05	일동제약주식회사	게피티닙의 개선된 제조방법
WO2016123391A1 (en)	2015-01-29	2016-08-04	Genentech, Inc.	Therapeutic compounds and uses thereof
CN107438593B (zh)	2015-01-30	2020-10-30	基因泰克公司	治疗化合物及其用途
JP6792546B2 (ja)	2015-02-25	2020-11-25	エーザイ・アール・アンド・ディー・マネジメント株式会社	キノリン誘導体の苦味抑制方法
MA41598A (fr)	2015-02-25	2018-01-02	Constellation Pharmaceuticals Inc	Composés thérapeutiques de pyridazine et leurs utilisations
CA2978226A1 (en)	2015-03-04	2016-09-09	Merck Sharpe & Dohme Corp.	Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
EP3272746B1 (en) *	2015-03-20	2019-12-25	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Salts of quinazoline derivative and method for preparing same
MX2017012805A (es)	2015-04-07	2018-04-11	Genentech Inc	Complejo de unión a antígenos con actividad agonista y métodos de uso.
JP7048319B2 (ja)	2015-05-12	2022-04-05	ジェネンテック，インコーポレイテッド	癌のための治療方法及び診断方法
JP7144935B2 (ja)	2015-05-29	2022-09-30	ジェネンテック，インコーポレイテッド	癌のための治療方法及び診断方法
MX2017014740A (es)	2015-06-08	2018-08-15	Genentech Inc	Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
MX2017015937A (es)	2015-06-08	2018-12-11	Genentech Inc	Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
CN107801379B (zh)	2015-06-16	2021-05-25	卫材R&D管理有限公司	抗癌剂
EP3310815A1 (en)	2015-06-17	2018-04-25	F. Hoffmann-La Roche AG	Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
KR102603199B1 (ko)	2015-06-22	2023-11-16	아레나 파마슈티칼스, 인크.	Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
US10287401B2 (en)	2015-07-01	2019-05-14	California Institute Of Technology	Cationic mucic acid polymer-based delivery systems
EP3331919A1 (en)	2015-08-07	2018-06-13	GlaxoSmithKline Intellectual Property Development Limited	Combination therapy comprising anti ctla-4 antibodies
EP3341376B1 (en)	2015-08-26	2020-12-23	Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO)	Condensed tricyclic compounds as protein kinase inhibitors
US10935544B2 (en)	2015-09-04	2021-03-02	Obi Pharma, Inc.	Glycan arrays and method of use
WO2017044434A1 (en)	2015-09-11	2017-03-16	Sunshine Lake Pharma Co., Ltd.	Substituted heteroaryl compounds and methods of use
GB201516905D0 (en)	2015-09-24	2015-11-11	Stratified Medical Ltd	Treatment of Neurodegenerative diseases
CN105250228B (zh) *	2015-10-12	2017-10-24	山东罗欣药业集团股份有限公司	一种吉非替尼的片剂及其原料的制备方法
JP2018532750A (ja)	2015-11-02	2018-11-08	ノバルティスアーゲー	ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン
WO2017093942A1 (en)	2015-12-01	2017-06-08	Glaxosmithkline Intellectual Property Development Limited	Combination treatments and uses and methods thereof
AU2016369528B2 (en)	2015-12-16	2021-04-22	Genentech, Inc.	Process for the preparation of tricyclic PI3K inhibitor compounds and methods for using the same for the treatment of cancer
JP6871255B2 (ja)	2015-12-30	2021-05-12	シントン・ベスローテン・フェンノートシャップ	ゲフィチニブの結晶形ａを製造する方法
CN105503748A (zh) *	2015-12-31	2016-04-20	哈药集团技术中心	一种吉非替尼的制备方法
ES2837428T3 (es)	2016-01-08	2021-06-30	Hoffmann La Roche	Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
JP6821693B2 (ja)	2016-02-29	2021-01-27	ジェネンテック，インコーポレイテッド	がんのための治療方法及び診断方法
CN109311995A (zh)	2016-03-29	2019-02-05	台湾浩鼎生技股份有限公司	抗体、药物组合物和方法
US10980894B2 (en)	2016-03-29	2021-04-20	Obi Pharma, Inc.	Antibodies, pharmaceutical compositions and methods
US20170319688A1 (en)	2016-04-14	2017-11-09	Genentech, Inc.	Anti-rspo3 antibodies and methods of use
KR20180134347A (ko)	2016-04-15	2018-12-18	제넨테크, 인크.	암의 진단 및 치료 방법
WO2017181079A2 (en)	2016-04-15	2017-10-19	Genentech, Inc.	Methods for monitoring and treating cancer
KR20190003958A (ko)	2016-04-15	2019-01-10	제넨테크, 인크.	암의 치료 및 모니터링 방법
US11261187B2 (en)	2016-04-22	2022-03-01	Duke University	Compounds and methods for targeting HSP90
BR112018071683A2 (pt)	2016-04-22	2019-02-19	Obi Pharma, Inc.	método para tratar um câncer de mama, método para tratamento de um tumor em um paciente, método para tratar um indivíduo sofrendo com câncer por imunoterapia, método para induzir/melhorar uma resposta imune em um indivíduo, método para melhorar a vacina obi-822 induzida pela resposta imune em um indivíduo necessitando da mesma, método para identificar um paciente adequado para terapia do câncer e método para determinar o prognóstico do tratamento do câncer ou resposta do fármaco de um paciente
EP3454863A1 (en)	2016-05-10	2019-03-20	INSERM (Institut National de la Santé et de la Recherche Médicale)	Combinations therapies for the treatment of cancer
KR101796684B1 (ko) *	2016-05-19	2017-11-10	건국대학교 산학협력단	케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
JP7160688B2 (ja)	2016-05-24	2022-10-25	ジェネンテック，インコーポレイテッド	Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
CN109476663B (zh)	2016-05-24	2021-11-09	基因泰克公司	用于治疗癌症的吡唑并吡啶衍生物
CN106045980B (zh) *	2016-06-03	2017-11-03	江苏开放大学	一种喹唑啉衍生物及其制备方法
ES2963807T3 (es)	2016-06-08	2024-04-02	Xencor Inc	Tratamiento de enfermedades relacionadas con la IgG4 con anticuerpos anti-CD19 de reticulación a CD32B
US20200129519A1 (en)	2016-06-08	2020-04-30	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
KR20230117482A (ko)	2016-07-27	2023-08-08	오비아이 파머 인코퍼레이티드	면역원성/치료 글리칸 조성물 및 그의 용도
KR102528998B1 (ko)	2016-07-29	2023-05-03	오비아이 파머 인코퍼레이티드	인간 항체, 제약 조성물 및 방법
US11649289B2 (en)	2016-08-04	2023-05-16	Glaxosmithkline Intellectual Property Development Limited	Anti-ICOS and anti-PD-1 antibody combination therapy
EP3494139B1 (en)	2016-08-05	2022-01-12	F. Hoffmann-La Roche AG	Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN109476748B (zh)	2016-08-08	2023-05-23	豪夫迈·罗氏有限公司	用于癌症的治疗和诊断方法
US20190209669A1 (en)	2016-08-23	2019-07-11	Oncopep, Inc.	Peptide vaccines and durvalumab for treating breast cancer
WO2018039203A1 (en)	2016-08-23	2018-03-01	Oncopep, Inc.	Peptide vaccines and durvalumab for treating multiple myeloma
CN106432202B (zh) *	2016-09-22	2019-04-02	郑州大学第一附属医院	喹唑啉类衍生物及其应用
CA3035080A1 (en)	2016-09-27	2018-04-05	Cero Therapeutics, Inc.	Chimeric engulfment receptor molecules
WO2018060833A1 (en)	2016-09-27	2018-04-05	Novartis Ag	Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US10927083B2 (en)	2016-09-29	2021-02-23	Duke University	Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
US10207998B2 (en)	2016-09-29	2019-02-19	Duke University	Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
EP3523451A1 (en)	2016-10-06	2019-08-14	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
WO2018078143A1 (en)	2016-10-28	2018-05-03	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Means and methods for determining efficacy of anti-egfr inhibitors in colorectal cancer (crc) therapy
JP2019535250A (ja)	2016-10-29	2019-12-12	ジェネンテック，インコーポレイテッド	抗ｍｉｃ抗体及び使用方法
KR20190077103A (ko)	2016-11-21	2019-07-02	오비아이 파머 인코퍼레이티드	접합된 생물학적 분자, 제약 조성물 및 방법
BR112019012976A2 (pt)	2016-12-22	2019-12-31	Amgen Inc	inibidores de kras g12c e métodos de uso dos mesmos
MX2019010295A (es)	2017-03-01	2019-11-21	Genentech Inc	Métodos de diagnóstico y terapéuticos para el cáncer.
US9980967B1 (en)	2017-03-16	2018-05-29	National Chiao Tung University	Method for overcoming drug resistance of EGFR mutation and cancerous stemness of human non-small cell lung carcinoma
AU2018250875A1 (en)	2017-04-13	2019-10-03	F. Hoffmann-La Roche Ag	An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
AU2018304458B2 (en)	2017-07-21	2021-12-09	Foundation Medicine, Inc.	Therapeutic and diagnostic methods for cancer
MX2020000903A (es)	2017-08-11	2020-07-22	Genentech Inc	Anticuerpos anti-cd8 y usos de los mismos.
EP3679159A1 (en)	2017-09-08	2020-07-15	H. Hoffnabb-La Roche Ag	Diagnostic and therapeutic methods for cancer
IL293443A (en)	2017-09-08	2022-07-01	Amgen Inc	kras g12c inhibitors and methods of using them
CA3073421A1 (en)	2017-09-26	2019-04-04	Daniel Mark COREY	Chimeric engulfment receptor molecules and methods of use
JP2021500409A (ja)	2017-10-24	2021-01-07	オンコペップ，インコーポレイテッド	乳がんを処置するためのペプチドワクチンおよびペムブロリズマブ
WO2019083960A1 (en)	2017-10-24	2019-05-02	Oncopep, Inc.	PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
CN109721552B (zh) *	2017-10-30	2022-09-20	上海北卡医药技术有限公司	一种吉非替尼的制备方法
MX2020004567A (es)	2017-11-06	2020-08-13	Genentech Inc	Metodos diagnosticos y terapeuticos para el cancer.
JP7254076B2 (ja)	2017-11-19	2023-04-07	サンシャイン・レイク・ファーマ・カンパニー・リミテッド	置換ヘテロアリール化合物及び使用方法
WO2019126136A2 (en)	2017-12-18	2019-06-27	Sterngreene, Inc.	Pyrimidine compounds useful as tyrosine kinase inhibitors
EP3730483B1 (en)	2017-12-21	2023-08-30	Hefei Institutes of Physical Science, Chinese Academy of Sciences	Class of pyrimidine derivative kinase inhibitors
AU2019209960B2 (en)	2018-01-20	2023-11-23	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine compounds and methods of use
MA51672A (fr)	2018-01-26	2020-12-02	Exelixis Inc	Composés destinés au traitement des troubles kinases-dépendants
US11673897B2 (en)	2018-01-26	2023-06-13	Exelixis, Inc.	Compounds for the treatment of kinase-dependent disorders
CA3088200A1 (en)	2018-01-26	2019-08-01	Exelixis, Inc.	Compounds for the treatment of kinase-dependent disorders
US20200399376A1 (en)	2018-02-26	2020-12-24	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
WO2019191334A1 (en)	2018-03-28	2019-10-03	Cero Therapeutics, Inc.	Chimeric tim4 receptors and uses thereof
RU2020135107A (ru)	2018-03-28	2022-04-29	Серо Терапьютикс, Инк.	Клеточные иммунотерапевтические композиции и их применения
CA3093969A1 (en)	2018-03-28	2019-10-03	Cero Therapeutics, Inc.	Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
BR112020020246A8 (pt) *	2018-04-05	2022-10-18	Sumitomo Dainippon Pharma Oncology Inc	Inibidores de cinase axl e uso dos mesmos
CA3099118A1 (en)	2018-05-04	2019-11-07	Amgen Inc.	Kras g12c inhibitors and methods of using the same
WO2019213516A1 (en)	2018-05-04	2019-11-07	Amgen Inc.	Kras g12c inhibitors and methods of using the same
CN108395410A (zh) *	2018-05-09	2018-08-14	日照市普达医药科技有限公司	一种苯胺喹唑啉化合物及其在抗肿瘤药物中的应用
CA3099045A1 (en)	2018-05-10	2019-11-14	Amgen Inc.	Kras g12c inhibitors for the treatment of cancer
AU2019275404A1 (en)	2018-05-21	2020-12-03	Nanostring Technologies, Inc.	Molecular gene signatures and methods of using same
US11096939B2 (en)	2018-06-01	2021-08-24	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
AU2019284472A1 (en)	2018-06-11	2020-11-26	Amgen Inc.	KRAS G12C inhibitors for treating cancer
WO2020050890A2 (en)	2018-06-12	2020-03-12	Amgen Inc.	Kras g12c inhibitors and methods of using the same
BR112020026384A2 (pt)	2018-06-23	2021-03-30	Genentech, Inc.	Métodos para tratar um indivíduo com câncer de pulmão e para tratar um indivíduo com câncer de pulmão de pequenas células, kits, anticorpo anti-pd-l1 e composição
US11203645B2 (en)	2018-06-27	2021-12-21	Obi Pharma, Inc.	Glycosynthase variants for glycoprotein engineering and methods of use
CA3104147A1 (en)	2018-07-18	2020-01-23	Genentech, Inc.	Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
EP3826988A4 (en)	2018-07-24	2023-03-22	Hygia Pharmaceuticals, LLC	COMPOUNDS, DERIVATIVES AND ANALOGS AGAINST CANCER
KR20210038906A (ko)	2018-07-26	2021-04-08	스미토모 다이니폰 파마 온콜로지, 인크.	비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
WO2020051099A1 (en)	2018-09-03	2020-03-12	Genentech, Inc.	Carboxamide and sulfonamide derivatives useful as tead modulators
WO2020061060A1 (en)	2018-09-19	2020-03-26	Genentech, Inc.	Therapeutic and diagnostic methods for bladder cancer
EP4249917A3 (en)	2018-09-21	2023-11-08	F. Hoffmann-La Roche AG	Diagnostic methods for triple-negative breast cancer
CN113194954A (zh)	2018-10-04	2021-07-30	国家医疗保健研究所	用于治疗角皮病的egfr抑制剂
EP3867646A1 (en)	2018-10-18	2021-08-25	F. Hoffmann-La Roche AG	Diagnostic and therapeutic methods for sarcomatoid kidney cancer
JP2020090482A (ja)	2018-11-16	2020-06-11	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
WO2020106640A1 (en)	2018-11-19	2020-05-28	Amgen Inc.	Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3898626A1 (en)	2018-12-19	2021-10-27	Array Biopharma, Inc.	Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020131674A1 (en)	2018-12-19	2020-06-25	Array Biopharma Inc.	7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
WO2020132651A1 (en)	2018-12-20	2020-06-25	Amgen Inc.	Kif18a inhibitors
TW202034924A (zh)	2018-12-20	2020-10-01	美商安進公司	Kif18a 抑制劑
MX2021007158A (es)	2018-12-20	2021-08-16	Amgen Inc	Heteroarilamidas utiles como inhibidores de kif18a.
US20220002311A1 (en)	2018-12-20	2022-01-06	Amgen Inc.	Kif18a inhibitors
TW202038957A (zh)	2018-12-21	2020-11-01	日商第一三共股份有限公司	抗體-藥物結合物與激酶抑制劑之組合
CN113924317A (zh)	2019-02-01	2022-01-11	葛兰素史克知识产权开发有限公司	贝兰他单抗莫福汀与派姆单抗组合用于治疗癌症
CN113396230A (zh)	2019-02-08	2021-09-14	豪夫迈·罗氏有限公司	癌症的诊断和治疗方法
JP2022521773A (ja)	2019-02-27	2022-04-12	ジェネンテック，インコーポレイテッド	抗ｔｉｇｉｔ抗体と抗ｃｄ２０抗体又は抗ｃｄ３８抗体とによる処置のための投薬
US20220146495A1 (en)	2019-02-27	2022-05-12	Epiaxis Therapeutics Pty Ltd	Methods and agents for assessing t-cell function and predicting response to therapy
KR20210146288A (ko)	2019-03-01	2021-12-03	레볼루션 메디슨즈, 인크.	이환식 헤테로사이클릴 화합물 및 이의 용도
EP3931195A1 (en)	2019-03-01	2022-01-05	Revolution Medicines, Inc.	Bicyclic heteroaryl compounds and uses thereof
WO2020223233A1 (en)	2019-04-30	2020-11-05	Genentech, Inc.	Prognostic and therapeutic methods for colorectal cancer
EP3962947A2 (en)	2019-05-03	2022-03-09	F. Hoffmann-La Roche AG	Methods of treating cancer with an anti-pd-l1 antibody
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
JOP20210310A1 (ar)	2019-05-21	2023-01-30	Amgen Inc	أشكال الحالة الصلبة
JP2022539178A (ja)	2019-06-26	2022-09-07	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド	Ｉｌ１ｒａｐ結合タンパク質
CN112300279A (zh)	2019-07-26	2021-02-02	上海复宏汉霖生物技术股份有限公司	针对抗cd73抗体和变体的方法和组合物
MX2022001302A (es)	2019-08-02	2022-03-02	Amgen Inc	Inhibidores de kif18a.
MX2022001181A (es)	2019-08-02	2022-02-22	Amgen Inc	Inhibidores de kif18a.
CN114401953A (zh)	2019-08-02	2022-04-26	美国安进公司	Kif18a抑制剂
MX2022001295A (es)	2019-08-02	2022-02-22	Amgen Inc	Inhibidores de kif18a.
TW202124439A (zh)	2019-09-04	2021-07-01	美商建南德克公司	Ｃｄ８結合劑及其用途
WO2021046289A1 (en)	2019-09-06	2021-03-11	Glaxosmithkline Intellectual Property Development Limited	Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and ipilimumab
WO2021043961A1 (en)	2019-09-06	2021-03-11	Glaxosmithkline Intellectual Property Development Limited	Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
JP2022551422A (ja)	2019-09-26	2022-12-09	エグゼリクシス，インコーポレイテッド	ピリドン化合物およびタンパク質キナーゼの調節における使用の方法
JP2022548978A (ja)	2019-09-27	2022-11-22	ジェネンテック，インコーポレイテッド	薬抗ｔｉｇｉｔ及び抗ｐｄ－ｌ１アンタゴニスト抗体を用いた処置のための投薬
EP4038097A1 (en)	2019-10-03	2022-08-10	Cero Therapeutics, Inc.	Chimeric tim4 receptors and uses thereof
MX2022004656A (es)	2019-10-24	2022-05-25	Amgen Inc	Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
CN114728936A (zh)	2019-10-29	2022-07-08	豪夫迈·罗氏有限公司	用于治疗癌症的双功能化合物
US11739074B2 (en)	2019-11-04	2023-08-29	Revolution Medicines, Inc.	Ras inhibitors
AU2020379734A1 (en)	2019-11-04	2022-05-05	Revolution Medicines, Inc.	Ras inhibitors
CA3160142A1 (en)	2019-11-04	2021-05-14	Revolution Medicines, Inc.	Ras inhibitors
MX2022005400A (es)	2019-11-06	2022-05-24	Genentech Inc	Metodos de diagnostico y terapeuticos para el tratamiento de canceres hematologicos.
AU2020380315A1 (en)	2019-11-08	2022-05-26	Revolution Medicines, Inc.	Bicyclic heteroaryl compounds and uses thereof
WO2021094379A1 (en)	2019-11-12	2021-05-20	Astrazeneca Ab	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CA3155989A1 (en)	2019-11-13	2021-05-20	Jason Robert ZBIEG	Therapeutic compounds and methods of use
US20220395553A1 (en)	2019-11-14	2022-12-15	Cohbar, Inc.	Cxcr4 antagonist peptides
CN114728960A (zh)	2019-11-14	2022-07-08	美国安进公司	Kras g12c抑制剂化合物的改善的合成
AU2020383535A1 (en)	2019-11-14	2022-05-05	Amgen Inc.	Improved synthesis of KRAS G12C inhibitor compound
CN114980976A (zh)	2019-11-27	2022-08-30	锐新医药公司	共价ras抑制剂及其用途
AU2020403145A1 (en)	2019-12-13	2022-07-07	Genentech, Inc.	Anti-Ly6G6D antibodies and methods of use
AU2020408562A1 (en)	2019-12-20	2022-06-23	Erasca, Inc.	Tricyclic pyridones and pyrimidones
WO2021142026A1 (en)	2020-01-07	2021-07-15	Revolution Medicines, Inc.	Shp2 inhibitor dosing and methods of treating cancer
MX2022008874A (es)	2020-01-20	2022-08-11	Astrazeneca Ab	Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
WO2021194481A1 (en)	2020-03-24	2021-09-30	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
TW202142230A (zh)	2020-01-27	2021-11-16	美商建南德克公司	用於以抗ｔｉｇｉｔ拮抗體抗體治療癌症之方法
WO2022050954A1 (en)	2020-09-04	2022-03-10	Genentech, Inc.	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
CN115038466A (zh)	2020-01-28	2022-09-09	葛兰素史密斯克莱知识产权发展有限公司	联合治疗及其用途和方法
WO2021177980A1 (en)	2020-03-06	2021-09-10	Genentech, Inc.	Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
WO2021233534A1 (en)	2020-05-20	2021-11-25	Pvac Medical Technologies Ltd	Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
WO2021185844A1 (en)	2020-03-16	2021-09-23	Pvac Medical Technologies Ltd	Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
US20230158152A1 (en) *	2020-03-17	2023-05-25	Medshine Discovery Inc.	Proteolysis regulator and method for using same
CN115698717A (zh)	2020-04-03	2023-02-03	基因泰克公司	癌症的治疗和诊断方法
WO2021222167A1 (en)	2020-04-28	2021-11-04	Genentech, Inc.	Methods and compositions for non-small cell lung cancer immunotherapy
CN113801068A (zh) *	2020-06-15	2021-12-17	鲁南制药集团股份有限公司	一种吉非替尼的有机酸盐
KR20230025691A (ko)	2020-06-16	2023-02-22	제넨테크, 인크.	삼중 음성 유방암을 치료하기 위한 방법과 조성물
WO2021257736A1 (en)	2020-06-18	2021-12-23	Revolution Medicines, Inc.	Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
WO2021257124A1 (en)	2020-06-18	2021-12-23	Genentech, Inc.	Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
JP2023531305A (ja)	2020-06-30	2023-07-21	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	術前補助療法後の固形癌患者の再発及び／又は死亡のリスクを予測するための方法。
CN115843335A (zh)	2020-06-30	2023-03-24	国家医疗保健研究所	用于预测患有实体癌的患者在术前辅助治疗和根治性手术后复发和/或死亡风险的方法
US11787775B2 (en)	2020-07-24	2023-10-17	Genentech, Inc.	Therapeutic compounds and methods of use
JP2023536602A (ja)	2020-08-03	2023-08-28	ジェネンテック，インコーポレイテッド	リンパ腫のための診断及び治療方法
JP2023536346A (ja)	2020-08-05	2023-08-24	エリプシーズファーマリミテッド	シクロデキストリン含有ポリマートポイソメラーゼ阻害剤コンジュゲートおよびｐａｒｐ阻害剤を用いた癌の処置
WO2022036146A1 (en)	2020-08-12	2022-02-17	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
WO2022036265A1 (en)	2020-08-14	2022-02-17	Cero Therapeutics, Inc.	Chimeric tim receptors and uses thereof
WO2022036287A1 (en)	2020-08-14	2022-02-17	Cero Therapeutics, Inc.	Anti-cd72 chimeric receptors and uses thereof
WO2022036285A1 (en)	2020-08-14	2022-02-17	Cero Therapeutics, Inc.	Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
AU2021332460A1 (en)	2020-08-27	2023-04-06	Enosi Therapeutics Corporation	Methods and compositions to treat autoimmune diseases and cancer
CN116209438A (zh)	2020-09-03	2023-06-02	锐新医药公司	使用sos1抑制剂治疗具有shp2突变的恶性疾病
CN116457358A (zh)	2020-09-15	2023-07-18	锐新医药公司	作为ras抑制剂以治疗癌症的吲哚衍生物
MX2023003338A (es)	2020-09-23	2023-06-14	Erasca Inc	Piridonas y pirimidonas tricíclicas.
CA3193952A1 (en)	2020-10-05	2022-04-14	Bernard Martin Fine	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202237638A (zh)	2020-12-09	2022-10-01	日商武田藥品工業股份有限公司	烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
US20230107642A1 (en)	2020-12-18	2023-04-06	Erasca, Inc.	Tricyclic pyridones and pyrimidones
CA3203111A1 (en)	2020-12-22	2022-06-30	Kailiang Wang	Sos1 inhibitors and uses thereof
CN112321814B (zh) *	2020-12-30	2021-03-23	广州初曲科技有限公司	一种吉非替尼艾地苯醌轭合物的制备及用途
AU2022221124A1 (en)	2021-02-12	2023-08-03	F. Hoffmann-La Roche Ag	Bicyclic tetrahydroazepine derivatives for the treatment of cancer
EP4294804A1 (en)	2021-02-19	2023-12-27	Exelixis, Inc.	Pyridone compounds and methods of use
IL305411A (en)	2021-02-26	2023-10-01	Kelonia Therapeutics Inc	Lymphocyte-targeted lentiviral vectors
WO2022235870A1 (en)	2021-05-05	2022-11-10	Revolution Medicines, Inc.	Ras inhibitors for the treatment of cancer
EP4334324A1 (en)	2021-05-05	2024-03-13	Revolution Medicines, Inc.	Covalent ras inhibitors and uses thereof
EP4334321A1 (en)	2021-05-05	2024-03-13	Revolution Medicines, Inc.	Ras inhibitors
KR20240026948A (ko)	2021-05-25	2024-02-29	에라스카, 아이엔씨.	황 함유 헤테로방향족 트리사이클릭 kras 억제제
WO2022266206A1 (en)	2021-06-16	2022-12-22	Erasca, Inc.	Kras inhibitor conjugates
CN113527266A (zh) *	2021-06-23	2021-10-22	上海健康医学院	一种靶向fap的双氧水响应的前药及其制备方法与应用
CN113336742B (zh)	2021-06-29	2022-05-10	山东金吉利新材料有限公司	一种马来酸吡咯替尼中间体的合成方法
CA3226019A1 (en)	2021-07-20	2023-01-26	Ags Therapeutics Sas	Extracellular vesicles from microalgae, their preparation, and uses
WO2023010097A1 (en)	2021-07-28	2023-02-02	Cero Therapeutics, Inc.	Chimeric tim4 receptors and uses thereof
TW202321261A (zh)	2021-08-10	2023-06-01	美商伊瑞斯卡公司	選擇性ｋｒａｓ抑制劑
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
CN113845485B (zh) *	2021-10-22	2023-03-14	湖南中医药大学	氨基酸衍生物及其制备方法和应用
WO2023097195A1 (en)	2021-11-24	2023-06-01	Genentech, Inc.	Therapeutic indazole compounds and methods of use in the treatment of cancer
TW202340212A (zh)	2021-11-24	2023-10-16	美商建南德克公司	治療性化合物及其使用方法
WO2023114954A1 (en)	2021-12-17	2023-06-22	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
WO2023144127A1 (en)	2022-01-31	2023-08-03	Ags Therapeutics Sas	Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en)	2022-03-08	2023-09-14	Revolution Medicines, Inc.	Methods for treating immune refractory lung cancer
WO2023187037A1 (en)	2022-03-31	2023-10-05	Astrazeneca Ab	Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer
WO2023191816A1 (en)	2022-04-01	2023-10-05	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023219613A1 (en)	2022-05-11	2023-11-16	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2023240058A2 (en)	2022-06-07	2023-12-14	Genentech, Inc.	Prognostic and therapeutic methods for cancer
WO2023240263A1 (en)	2022-06-10	2023-12-14	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
WO2024002938A1 (en)	2022-06-27	2024-01-04	Astrazeneca Ab	Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2024015897A1 (en)	2022-07-13	2024-01-18	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024020432A1 (en)	2022-07-19	2024-01-25	Genentech, Inc.	Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024030441A1 (en)	2022-08-02	2024-02-08	National University Corporation Hokkaido University	Methods of improving cellular therapy with organelle complexes
WO2024033389A1 (en)	2022-08-11	2024-02-15	F. Hoffmann-La Roche Ag	Bicyclic tetrahydrothiazepine derivatives
WO2024033458A1 (en)	2022-08-11	2024-02-15	F. Hoffmann-La Roche Ag	Bicyclic tetrahydroazepine derivatives
WO2024033388A1 (en)	2022-08-11	2024-02-15	F. Hoffmann-La Roche Ag	Bicyclic tetrahydrothiazepine derivatives
WO2024033457A1 (en)	2022-08-11	2024-02-15	F. Hoffmann-La Roche Ag	Bicyclic tetrahydrothiazepine derivatives

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3266990A (en) *	1963-09-24	1966-08-16	Warner Lambert Pharmaceutical	Derivatives of quinazoline
JPS5538325A (en) *	1978-09-11	1980-03-17	Sankyo Co Ltd	4-anilinoquinazoline derivative and its preparation
US4343940A (en) *	1979-02-13	1982-08-10	Mead Johnson & Company	Anti-tumor quinazoline compounds
GB2160201B (en) *	1984-06-14	1988-05-11	Wyeth John & Brother Ltd	Quinazoline and cinnoline derivatives
ATE110071T1 (de) *	1988-01-23	1994-09-15	Kyowa Hakko Kogyo Kk	Pyridazinon-derivate und diese enthaltende pharmazeutische zubereitungen.
IL89029A (en) *	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
HUT64755A (en) *	1991-02-20	1994-02-28	Pfizer	Process for the production of 2,4-diamino-quinazoline derivatives and of medical preparatives containing them
CA2102780C (en) *	1991-05-10	2007-01-09	Alfred P. Spada	Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5721237A (en) *	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) *	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
NZ243082A (en) *	1991-06-28	1995-02-24	Ici Plc	4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) *	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
US6177401B1 (en) *	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) *	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
GB9314893D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Quinazoline derivatives
GB9314884D0 (en) *	1993-07-19	1993-09-01	Zeneca Ltd	Tricyclic derivatives
EP0668280A1 (en) *	1993-09-03	1995-08-23	Kyowa Hakko Kogyo Co., Ltd.	Imidazoquinazoline derivative
US5409000A (en) *	1993-09-14	1995-04-25	Cardiac Pathways Corporation	Endocardial mapping and ablation system utilizing separately controlled steerable ablation catheter with ultrasonic imaging capabilities and method
GB9325217D0 (en) *	1993-12-09	1994-02-09	Zeneca Ltd	Pyrimidine derivatives
US5700823A (en) *	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
IL112248A0 (en) *	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) *	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
BR9506936A (pt) *	1994-02-23	1997-09-09	Pfizer	Derivados de quinazolina substituídos com 4-heterociclila processos para sua preparaçao e seu uso como agentes anticancerosos
AU2096895A (en) *	1994-03-07	1995-09-25	Sugen, Incorporated	Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
DE59500788D1 (de) *	1994-05-03	1997-11-20	Ciba Geigy Ag	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
GB9510757D0 (en) *	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
TW321649B (xx) *	1994-11-12	1997-12-01	Zeneca Ltd
GB9424233D0 (en) *	1994-11-30	1995-01-18	Zeneca Ltd	Quinazoline derivatives
AU5108196A (en) *	1995-03-20	1996-10-08	Dr. Karl Thomae Gmbh	Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
DE19510019A1 (de) *	1995-03-20	1996-09-26	Thomae Gmbh Dr K	Imidazo[4,5-g]chinazoline, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP2163546B1 (en) *	1995-03-30	2016-06-01	Pfizer Products Inc.	Quinazoline derivatives
ES2150113T3 (es) *	1995-04-03	2000-11-16	Novartis Ag	Derivados de pirazol y procedimientos para la preparacion de los mismos.
EP0824525B1 (en) *	1995-04-27	2001-06-13	AstraZeneca AB	Quinazoline derivatives
GB9508537D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
GB9508535D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivative
GB9508565D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quiazoline derivative
IL117923A (en) *	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
DE69603240T2 (de) *	1995-05-12	2000-01-05	Neurogen Corp	Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
CA2222545A1 (en) *	1995-06-07	1996-12-19	Sugen, Inc.	Quinazolines and pharmaceutical compositions
EP0831829B1 (en) *	1995-06-07	2003-08-20	Pfizer Inc.	Heterocyclic ring-fused pyrimidine derivatives
BR9609617B1 (pt) *	1995-07-06	2010-07-27		derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
GB9514265D0 (en) *	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
GB9520822D0 (en) *	1995-10-11	1995-12-13	Wellcome Found	Therapeutically active compounds
AR004010A1 (es) *	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos

1995
- 1995-04-27 GB GBGB9508538.7A patent/GB9508538D0/en active Pending
1996
- 1996-04-08 TW TW085104049A patent/TW436486B/zh not_active IP Right Cessation
- 1996-04-23 NZ NZ305444A patent/NZ305444A/xx not_active IP Right Cessation
- 1996-04-23 JP JP8532252A patent/JP3040486B2/ja not_active Expired - Lifetime
- 1996-04-23 KR KR1019970707511A patent/KR100296656B1/ko not_active IP Right Cessation
- 1996-04-23 HU HU9802839A patent/HU223313B1/hu active Protection Beyond IP Right Term
- 1996-04-23 WO PCT/GB1996/000961 patent/WO1996033980A1/en active IP Right Grant
- 1996-04-23 RU RU97119521/04A patent/RU2153495C2/ru active Protection Beyond IP Right Term
- 1996-04-23 EP EP96910134A patent/EP0823900B1/en not_active Expired - Lifetime
- 1996-04-23 DE DE122009000076C patent/DE122009000076I1/de active Pending
- 1996-04-23 DE DE69611361T patent/DE69611361T2/de not_active Expired - Lifetime
- 1996-04-23 SK SK1454-97A patent/SK282236B6/sk not_active IP Right Cessation
- 1996-04-23 AU AU53433/96A patent/AU699163B2/en not_active Expired
- 1996-04-23 PL PL96323066A patent/PL189182B1/pl unknown
- 1996-04-23 EG EG35896A patent/EG24134A/xx active
- 1996-04-23 RO RO97-01978A patent/RO117849B1/ro unknown
- 1996-04-23 BR BRPI9608082A patent/BRPI9608082B8/pt not_active IP Right Cessation
- 1996-04-23 SI SI9630183T patent/SI0823900T1/xx unknown
- 1996-04-23 AT AT96910134T patent/ATE198329T1/de active
- 1996-04-23 CN CN96193526A patent/CN1100046C/zh not_active Expired - Lifetime
- 1996-04-23 CZ CZ19973396A patent/CZ288489B6/cs not_active IP Right Cessation
- 1996-04-23 ES ES96910134T patent/ES2153098T3/es not_active Expired - Lifetime
- 1996-04-23 PT PT96910134T patent/PT823900E/pt unknown
- 1996-04-23 DK DK96910134T patent/DK0823900T3/da active
- 1996-04-23 UA UA97115677A patent/UA52602C2/uk unknown
- 1996-04-23 EE EE9700252A patent/EE03482B1/xx active Protection Beyond IP Right Term
- 1996-04-23 CA CA002215732A patent/CA2215732C/en not_active Expired - Lifetime
- 1996-04-24 AR ARP960102305A patent/AR003944A1/es unknown
- 1996-04-25 HR HR960204A patent/HRP960204B1/xx not_active IP Right Cessation
- 1996-04-25 MY MYPI96001577A patent/MY114425A/en unknown
- 1996-04-26 ZA ZA963358A patent/ZA963358B/xx unknown
- 1996-04-26 US US08/638,331 patent/US5770599A/en not_active Expired - Lifetime
- 1996-04-26 IL IL11804596A patent/IL118045A/en active Protection Beyond IP Right Term
1997
- 1997-10-24 NO NO974940A patent/NO309472B1/no not_active IP Right Cessation
- 1997-11-18 BG BG102052A patent/BG62730B1/bg unknown
1998
- 1998-05-25 HK HK98104504A patent/HK1005371A1/xx not_active IP Right Cessation
2001
- 2001-01-11 GR GR20010400025T patent/GR3035211T3/el unknown
2009
- 2009-12-15 FR FR09C0065C patent/FR09C0065I2/fr active Active
- 2009-12-16 NO NO2009028C patent/NO2009028I1/no unknown
- 2009-12-17 LU LU91631C patent/LU91631I2/fr unknown
- 2009-12-17 NL NL300429C patent/NL300429I1/nl unknown

Also Published As

Publication number	Publication date
BG102052A (en)	1998-08-31
DE122009000076I1 (de)	2010-05-06
PT823900E (pt)	2001-04-30
BG62730B1 (bg)	2000-06-30
FR09C0065I1 (xx)	2010-01-22
DE69611361D1 (de)	2001-02-01
ZA963358B (en)	1996-10-28
HRP960204B1 (en)	2001-10-31
EG24134A (en)	2008-08-06
CA2215732A1 (en)	1996-10-31
AU699163B2 (en)	1998-11-26
HU223313B1 (hu)	2004-05-28
CZ339697A3 (cs)	1998-02-18
RU2153495C2 (ru)	2000-07-27
FR09C0065I2 (fr)	2014-03-28
WO1996033980A1 (en)	1996-10-31
LU91631I2 (fr)	2010-02-17
BRPI9608082A (pt)	1999-01-26
BRPI9608082B8 (pt)	2021-07-06
AR003944A1 (es)	1998-09-30
GB9508538D0 (en)	1995-06-14
GR3035211T3 (en)	2001-04-30
MY114425A (en)	2002-10-31
BRPI9608082B1 (pt)	2019-04-30
ES2153098T3 (es)	2001-02-16
EP0823900A1 (en)	1998-02-18
IL118045A0 (en)	1996-08-04
EE9700252A (et)	1998-04-15
JPH11504033A (ja)	1999-04-06
SK282236B6 (sk)	2001-12-03
DK0823900T3 (da)	2001-04-02
NO974940D0 (no)	1997-10-24
NO2009028I2 (no)	2011-10-17
PL189182B1 (pl)	2005-07-29
CN1100046C (zh)	2003-01-29
CN1182421A (zh)	1998-05-20
NO974940L (no)	1997-10-24
SK145497A3 (en)	1998-02-04
UA52602C2 (uk)	2003-01-15
NO2009028I1 (no)	2014-05-19
CA2215732C (en)	2002-04-09
RO117849B1 (ro)	2002-08-30
TW436486B (en)	2001-05-28
AU5343396A (en)	1996-11-18
CZ288489B6 (en)	2001-06-13
EP0823900B1 (en)	2000-12-27
PL323066A1 (en)	1998-03-02
KR19990007987A (ko)	1999-01-25
EE03482B1 (et)	2001-08-15
JP3040486B2 (ja)	2000-05-15
US5770599A (en)	1998-06-23
KR100296656B1 (ko)	2001-08-07
IL118045A (en)	2001-10-31
HRP960204A2 (en)	1997-08-31
NL300429I1 (nl)	2010-03-01
HUP9802839A2 (hu)	1999-03-29
NO309472B1 (no)	2001-02-05
HUP9802839A3 (en)	2001-02-28
HK1005371A1 (en)	1999-01-08
ATE198329T1 (de)	2001-01-15
DE69611361T2 (de)	2001-04-26
NZ305444A (en)	1999-03-29

Publication	Publication Date	Title
DE69638352D1 (xx)	2011-05-19
DE69637714D1 (xx)	2008-11-27
BRPI9612258B1 (xx)	2011-05-31
BRPI9612138B1 (xx)	2009-09-22
DK143195A (xx)	1997-05-04
ECSDI950232S (xx)	1996-01-29
CH0741373H1 (xx)	2011-10-14
IN187108B (xx)	2002-02-02
DK0727898T3 (xx)	1997-03-17
ECSDI950230S (xx)	1996-07-16
ECSDI950229S (xx)	1996-01-29
ECSDI950223S (xx)	1996-01-29
ECSDI950231S (xx)	1996-01-29
BR7501503U (xx)	1997-11-25
ECSDI950233S (xx)	1996-01-29
BR7502120U (xx)	1998-04-14
DK126096A (xx)	1996-11-08
CN3034524S (xx)	1995-08-30
CN3037433S (xx)	1995-11-22
CN3032568S (xx)	1995-06-14
CN3032692S (xx)	1995-06-14
CN3033225S (xx)	1995-07-05
CN3033635S (xx)	1995-07-19
CN3033771S (xx)	1995-08-02
CN3031926S (xx)	1995-05-17